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INTRODUCTION 
Erectile dysfunction, known as impotence, is by no mean a modern phenomenon. It 
has been present throughout the ages. The word “impotence” derives from latin word 
“impotencia” that means lack of power and it has been already mentioned in the Old 
Testament of the Bible. In the ancient Egypt, people believed that impotence could be 
dependent on two causes: a natural one, where a man is not able to accomplish the sexual 
act, and a supernatural one; on the other hand, according to Greek mythology, impotence 
in adult life was caused by sexual anxiety during the childhood and in the middle ages it 
was believed to be caused by witches. Nevertheless, restrictive social attitudes and taboos 
have severely inhibited scientific investigation of human sexual function. In the 20th 
century a sort of sexual revolution came up and in recently many studies contributed to 
understand sexual anatomy and physiology and to introduce new concepts about sexual 
therapy, further lessening social barriers to open discussion about human sexual behaviour. 
Perhaps, progress in male sexual medicine accelerated in 1970s when, for the first 
time, sexual dysfunction was considered to be an endocrine or psychological problem. In 
these years, new surgical and pharmacological techniques were introduced for the 
treatment of erectile dysfunction (Michal et al., 1973; Michal et al., 1977). A specific 
development in sexual medicine occurred in 1992, when the National Institutes of Health 
in the United States recommended the use of the term erectile dysfunction rather than 
impotence and also defined erectile dysfunction as the “consistent inability to attain and/or 
maintain a penile erection, sufficient for an adequate sexual relation.  
In 1990s, thanks to the contribution of many studies elucidating mechanisms of 
penile physiology, it has been showed that the erection is regulated by a balance between 
relaxant and contracting factors and that the unbalancing of these mediators is causing 
erectile dysfunction. 
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1.1 Anatomy 
The human penis is composed of the paired corpora cavernosa and the single corpus 
spongiosum, which surround the urethra. The first controls the rigidity/flaccidity of the 
penis, while the second regulates the diameter of the urethra for urination/ejaculation. The 
proximal portion of the corpora cavernosa is firmly anchored to the pubic bone, but the 
distal end is covered by the glans penis. The corpora cavernosa are characterized by a 
spongy tissue structure of connective trabecular tissue surrounding vascular spaces named 
sinusoids. In addition the corpora cavernosa are surrounded by a fibroelastic covering, the 
tunica albuginea. During the erection, blood fills up sinusoids and its flow is regulated by 
helicine arteries, which are branches of the cavernous artery. Venules are instead, 
responsible for the drainage of the sinusoids from the subtunical venous plexuses, which 
traverse the tunica and empty into the dorsal and cavernous veins. 
The two corpora cavernosa and the corpus spongiosum are surrounded by Buck’s facia. 
The remaining superficial layers of the penis consist of subcutaneous cellular tissue, the 
superficial penile fascia (Dartos fascia) and the skin. The penis primarily is vascularised by 
pudendal artery, a branch of the internal iliac artery and it is divided into the bulborethral, 
dorsal and cavernosal arteries. All together these vessels supply the blood to the penis. 
Particularly the bulbourethral artery supplies the urethras and corpus spongiosum,  while 
the cavernosal arteries, entering the centre of corpora cavernosa, give rise to the elicine 
arteries, which in turn supply the sinusoidal spaces. The paired dorsal penile arteries 
proceed down the penis along with the dorsal nerves and supply superficial structure and 
glans penis as well as the corpora cavernosa via circumflex arteries. 
Instead, the superficial venous system consists of superficial dorsal veins, which drain 
the skin and the subcutaneous tissue above the buck’s fascia. The deep venous system 
starts with the subtunical venules draining the sinusoids, which merge to form the emissary 
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veins. These veins cross the tunica albuginea and drain into the circumflex veins which in 
turn join the deep dorsal vein beneath Buk’s fascia, which ends in the periprostatic venous 
plexus. The corpus spongiosum is drained by the bulbar and spongiosal veins which have 
many channels that communicate with the corpora cavernosa. The subtunical and emissary 
veins are compressed during erection.   
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Figure 1. Schematic illustration of human penis. 
(A) Lateral aspect of the penis. The penis leans on and is supported by a suspensory ligament, and 
terminates with glans penis. The corpora cavernosa, surrpunded by the tunica albuginea, are held by the 
bulbospongiosus muscle in which  the fibers are mostly transverse. The corpus cavernosum is entrapped in 
the ischiocavernosus muscle with the muscle fibers aligned in the longitudinal direction. 
(B) Medial aspect of the penis. The distal ligament, an inelastic fibrous structures, forms the trunk of the 
glans penis . The urethra is contained in the corpus spongiosum. 
(C) Ventral aspect of the penis. The ischiocavernosus muscle is paired with and situated at the lateral 
boundary of the perineum. The anterior fibers of the bulbospongiosus muscle partially radiate to encircle the 
corpus cavernosum and mostly insert into the ventral thickening of the tunica. 
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1.2 Physiology of penile erection 
Erection is the final common pathway of the integrative synchronized action of 
psychological, neuronal, hormonal, vascular, and cavernous smooth muscle systems.  
 
1.2.1.  Hemodynamic and mechanism of erection and detumescence 
Penile erection is an example of microcirculation where there is a predominance of 
adrenergic tone in the flaccid state of the penis (or turgid state) while its reduction occurs 
during the erect state (or rigid state). Initially the dilatation of arterioles and arteries causes 
an increase in blood flow and volume augmentation. Blood inflow provokes a shift from 
the turgid state to the full rigid state. The expansion of sinusoidal spaces traps the incoming 
blood in the corpora cavernosal due to the so called veno-occlusive mechanism: the 
compression of the subtunical venular plexus between the tunica albuginea and the 
peripheral sinusoids, in association to the stretching,  reduces the venous outflow. In fact 
the stretching of the tunica occludes the emissary veins between the inner circular and the 
outer longitudinal layers and further decreases the venous outflow to a minimum. The 
blood trapped within the corpora cavernosa produces the erect state of the penis, which is 
associated to an intracavernous pressure of approximately 100 mmHg (the full erection 
phase). During sexual activity, the bulbocavernosus reflex is activated and the 
ischiocavernosus muscles contract to forcefully compress the base of the blood-filled 
corpora cavernosa (rigid-erection phase) (Figure 2b). 
Erection thus involves sinusoidal relaxation, arterial dilatation, and venous 
compression (Lue et al.,983). The importance of smooth muscle relaxation has been 
demonstrated in animal and human studies (Saenz de Tejada et al., 1989; Ignarro et al., 
1990), while detumescence is characterized by three phases, as reported in an animal 
studies (Bosch et al., 1991). The first phase entails a transient increase in intracorporal 
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pressure, indicating the beginning of smooth muscle contraction against a closed venous 
system. The second phase shows a slow pressure decrease, suggesting a slow re-opening of 
the venous channels with resumption of the basal level of arterial flow. The third phase 
shows a fast pressure decrease with fully restored venous outflow capacity (Figure 2a). 
 
 
 
 
 
 
 
 
Figure 2. Hemodynamic and Mechanism of Erection and Detumescence 
 (A) In the flaccid state the arteries, arterioles and sinusoids are contracted. The intersinusoidal and 
subtunical venular plexus are open, allowing free flow to the emissary veins. 
(B) Initially a dilatation of the arterioles and arteries cause an increase of blood flow, followed by an 
expansion of sinusoidal spaces and volume augmentation. Once gathered in the sinusoidal spaces, the blood 
is trapped in the corporal cavernosal do to the so-called veno-occlusive mechanism. This process lead to the 
compression of the subtunical plexuses between the peripheral sinusoids and the tunica albuginea, thus 
reducing the venous outflow. 
 
 
Flaccid state 
Erect state 
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1.2.2. Neuroanatomy and neurophysiology of penile erection 
Penile erection involves a complex interaction between the central nervous system and 
local factors. Primarily, it is a neurovascular event modulated by the individual’s 
psychological and hormonal status. Sexual stimulation elicits nerves impulses that are 
carried to the penis to release neurotransmitters from the cavernous nerve terminals. 
The neuronal system involved in erection is often divided into spinal and supraspinal 
networks. It is generally accepted that the spinal system directly controls erection and that 
the supraspinal network modulates this control mechanism through different ascending and 
descending pathways. 
 
a) Spinal pathways 
Both autonomic (sympathetic – T12-L2 – and parasympathetic – S2-S4) and somatic 
(sensory and motor) nerves innervate the penis. The sympathetic and parasympathetic 
nerves from the neurons in the spinal cord and peripheral ganglia, merge to form the 
cavernous nerves, which enter the corpora cavernosa and corpus spongiosum to affect the 
neurovascular events during erection and detumescence. The somatic nerves are primarily 
responsible for sensation and the contraction of the bulbocavernosus and ischiocavernosus 
muscles. In particular, sympathetic pathways are anti-erectile, sacral parasympathetic 
pathways are pro-erectile, and contraction of the perineal striated muscles upon activity of 
the pudendal nerves improves penile rigidity. Spinal neurons controlling erection are 
activated by information from peripheral and supraspinal origin.  
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b) Supraspinal pathways 
Marson et al., (1993) and then Sachs et al., (1988) identified the medial preoptic area 
(MPOA) and the paraventricular nucleus (PVN) of the hypothalamus and hippocampus as 
important integration centers for sexual function and penile erection. 
Many studies, by using positron emission tomography (PET) and functional MRI 
(fMRI), demonstrated that central neuronal activation is responsible for three types of 
erection: psychogenic, reflexogenic and nocturnal (Robert et al., 2005). Psychogenic 
erection is the result of audiovisual stimuli or fantasy. Impulses from the brain modulate 
the spinal erection centers (T11-L2 and S2-S4) to activate the erectile process. 
Reflexogenic erection is produced by tactile stimuli to the genital organs. The impulses 
reach the spinal erection centers, then some of them follow the ascending tract, resulting in 
sensory perception, while others activate the autonomic nuclei to send messages via the 
cavernous nerves to the penis in order to induce erection. Nocturnal erection occurs mostly 
during rapid-eye-movement (REM) sleep. In human during REM sleep, an increased 
activity in the pontine area, the amygdalas and the anterior cingulate gyrus but decreased 
activity in the prefrontal and parietal cortex have been showed. Additionally, during REM 
sleep, the cholinergic neurons in the lateral pontine tegmentum are activated while the 
adrenergic neurons in the locus ceruleus and the serotoninergic neurons in the midbrain 
raphe are silent. This differential activation may be responsible for the nocturnal erections 
during REM sleep. 
 
1.2.3. The mediators involved in  Penile Erection 
The physiological mechanism of penile erection is characterized by a coordinated and 
intricate interplay between the pathways of vasorelaxation and vasoconstriction.  
Introduction: physiology and pathophisiology of erectile function  
 
 13 
The penis is maintained in a flaccid state by a predominance of α-adrenergic tone. In 
fact, this state is characterized by the contraction of penile arterial and corporal smooth 
muscle cells through activation of post-junctional α1-receptors mainly by increasing of 
intracellular calcium. In addition, noradrenaline inhibits vasodilatatory neurotransmitter 
release by prejunctional α2-adrenoceptors. 
Instead penile vasodilatation is mainly mediated by L-arginine/NO pathway through 
activation of guanylyl cyclase in smooth muscle component, followed by an increase in 
cGMP which in turn lowers intracellular calcium (Figure 3). 
 
 
 
Figure 3: Physiology of erection and the impact of PDE5 
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1.2.3.a Contraction 
 
 
 
Figure 4. Mechanisms of penile vascular smooth muscle contraction in the flaccid state. 
The release of noradrenaline (NA) and neuropeptide Y (NPY) from sympathetic nerves and increased 
formation of angiotensin II and endothelin in the endothelial cells are the causes of  the contraction of the 
penile smooth muscle. 
 
 
 
 The adrenergic system 
The cavernous trabecular smooth muscle cells and penile vasculature receive an 
adrenergic innervation (Tamura et al., 1995). As indicated by the erection induced after 
injection of α-adrenoceptor antagonist, sympathetic tone is the mainly responsible for 
maintenance the penis in the flaccid state (Wagner et al., 1989; Diederichs et al., 1990; 
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Giuliano et al., 1993). In 1980 Levin and Wein showed that in human corpus cavernosum 
α-adrenoceptor are almost ten times higher than β- receptor (Levin & Wein, 1980). 
Particularly, the human penile tissue exhibits a profile for α1-and α 2-adrenoceptor 
expression quantitatively and qualitatively similar (Goepel et al., 1999). mRNAs for the 
three α1-adrenoceptor subtypes (α1A, α1B, α1D) have been identified with a predominance of 
α1A (El-Gamal et al., 2006), while the contribute of α2-receptor is exclusively due to the 
α2A-subtype (Goepel et al., 1999). 
There are several clinical studies about the possible use of α-adrenoceptor antagonist in 
the treatment of erectile dysfunction and also some of these are crucial to understand the 
involvement of  the α-adrenoceptor in the physiology of penile erection: noradrenaline 
binds to postjunctional α1A-adrenoceptors and cause smooth muscle cells contraction, 
which in turn increases IP3 and intracellular calcium levels; calcium then binds to 
calmodulin and activates myosin light chain kinase (MLCK) as well as inhibits myosin 
light chain phosphatase (MLCP); moreover noradrenaline, by binding prejunctional α2-
adrenoceptor, inhibits the release of nitric oxide, while limit the overflow of noradrenaline 
by binding α2-autoceptor (Somlyo et al., 2000; Kimura et al., 1996). 
In addition, in 2003, Cirino et al. demonstrated the presence of β3-adrenoceptors in 
smooth muscle cells of human corpus cavernosum. This study showed that, in human 
penile tissue, the activation of β3-adrenoceptors leads to a cGMP dependent but NO-
indipendent relaxation blocked by a specific receptor antagonist. Besides, they 
demonstrated that human corpus cavernosum exhibits basal β3-receptor-mediated 
vasorelaxant tone and that β3-receptor activity is linked to inhibition of the Rho-kinase 
pathway (Cirino et al., 2003).  
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 Endothelin 
Endothelins (ETs), ET-1, ET-2 and ET-3, are a family of endogenous peptides mainly 
secreted by endothelial cells (Yanagisawa M, et al., 1988). These peptides exert a potent 
vasoconstrictor activity by acting through two different receptors, named ETA and ETB.  
Particular attention has focused on the role of endothelins as potential modulators of 
corpus cavernosum basal tone and their importance in maintaining smooth muscle cell 
contractility when the penis is in the flaccid state. Indeed, mRNA for ET-1 is expressed by 
endothelial cells of human penile tissue (Saenz de Tejada I, et al., 1991). Several studies 
have showes ET-1 as a potent agonist for vascular smooth muscle cell contraction (Christ 
et al., 1995; Saenz de Tejada et al., 1991.). ET-2 and ET-3 also causes contraction of 
smooth muscle in human penile tissue but they are less potent than ET-1 (Saenz de Tejada 
et al., 1991). 
The physiologic effects of ET-1 are mediated by increase of intracellular calcium levels 
in cells. ET-1, when released from endothelial cells into the surrounding tissue, binds its 
receptor at the target cells and facilitates an increase in calcium through inositol 
triphosphate and voltage-gated calcium channel based pathways (Marsden et al., 1989; 
Berridge et al., 1987; Rasmussen et al., 1987). 
In separately published reports, Christ et al and Zhao and Christ have shown ET-1 to 
be a potent agonist for smooth muscle contraction in tissues, suggesting its importance as a 
mediator for maintaining smooth muscle cells basal tone in the penis(Christ GJ, et al. 
1995; Zhao & Christ, 1995) 
 
 Angiotensin and angiotensin converting enzyme 
Angiotensin II (Ang II) is the main active metabolite of the renin-angiotensin cascade and 
it is produced by angiotensin-converting enzyme, which converts Ang I in Ang II. 
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Circulating Ang II influences blood pressure and systemic peripheral resistance. In 
mammalian cells it exerts its activity by binding two subtypes of plasma membrane 
receptors, AT1 and AT2 (Touyz & Schiffrin 2000). In erectile tissue, there is a local 
production of Ang II as angiotensin-converting enzyme is localised in the endothelium of 
human corpus cavernosum strips (Kifor et al., 1997; Park et al., 1997). Functional and 
binding studies in isolated corpus cavernosum strips showed that the angiotensin receptor 
subtype AT1 mediates the contraction evoked by exposure to Ang II (Kifor et al., 1997; 
Park et al., 1997). It has been demonstrated that, in men, Ang II plays an important role in 
regulation of flaccid state and detumescence of penis. Becker et al. confirmed the 
functional importance of Ang II in the penile erection by evaluation of peptide plasma 
levels. In particular, they demonstrated that in blood samples taken during flaccidity, 
tumescence, and rigidity, cavernous Ang II levels did not differ significantly; while during 
the detumescence phase, the increase in Ang II plasma levels was significantly higher if 
compared to other penile phases. (Becker et al., 2001). These results provide evidences for 
the physiological importance of this peptide in the termination of penile erection. 
 
 The Rho-kinase pathway 
As  previously described, the flaccid state of the penis is controlled by various contractile 
mediators by increasing of intracellular calcium and activating calcium sensitization. In 
fact the contraction is induced at constant intracellular calcium concentration by certain 
agonists are due to inhibition of the myosin phosphatase, whereas the inhibitory signal for 
calcium sensitization is provided by RhoA to Rho-kinase. RhoA, a monomeric G-protein 
activated by GTP and inactivated when the bound nucleotide is GDP, mediates calcium 
sensitization in erectile function. Indeed, activated RhoA-kinase phosphorylates the 
regulatory subunit of MLCP and inhibits phosphatase activity. Actually the importance of 
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calcium-sensitizing RhoA/Rho-kinase pathway is well known and it plays prominent role 
in the cavernosal vasoconstriction in order to maintain the flaccid state. This role has been 
demonstrated in 2001 by Chitaley et al. In a study carried out on rats, they showed, that the 
treatment with a Rho-kinase inhibitor in vitro induces relaxation while in vivo it caused a 
penile erection independent of nitric oxide (Chitaley et al., 2002).  
 
 
1.2.3.b Relaxation 
 
 
Figure. 5. Mechanisms of penile vascular smooth muscle relaxation in the erectile state. 
 The initial event in erection is vasodilation caused by nitric oxide (NO) released from the parasympathetic 
nerves and other NANC neurotransmitters. The increased flow through the penile arteries due to shear stress 
on the endothelial cells probably leads to release of NO, prostaglandins (PG), and a non-NO non-PG factor 
such as endothelium-derived hyperpolarizing factor (EDHF). 
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 L-arginine/NO pathway  
Substantial evidence has supported nitric oxide (NO) as the central component of signal 
transduction system that acts in the penis to mediate erectile response. The enzyme 
responsible for NO production is NO synthase  (NOS), expressed in main biological tissues 
as three different isoforms: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial 
NOS (eNOS) (Forstermann et al., 1998). The iNOS isoform, which primarily is expressed 
in immune system, is not perceived to be involved in normal penile erection. In fact iNOS 
represent another source of NO in smooth muscle cells but it requires cytokines stimulation 
for its expression (Figure 6). Instead, both eNOS or nNOS are constitutive isoform 
requiring calcium-binding protein calmodulin, oxygen, and reduced NADPH for catalytic 
activity. eNOS is located in caveolae (50–100 nm invaginations of the plasma membrane) 
where it is complexed with caveolin-1 (CAV-1), which decorates the cytoplasmic surface 
of caveolae and forms a physiological inhibitor of eNOS (Garcia-Cardena et al., 1997; 
Bucci et al. 2000). Following activation of endothelial cells by a cadre of mediators, CAV-
1-mediated inhibition is diminished by the recruitment of several proteins that promote an 
activation complex(Garcia-Cardena et al., 1997). The first protein shown to be involved in 
the regulation of eNOS was CaM. Another protein involved in the regulation of eNOS is 
heat shock protein 90 (HSP90), which directly binds to and activates eNOS in vitro 
causing NO release (García-Cardeña et al., 1998). Recently, HSP90 has been shown to 
influence the phosphorylation and coupling of eNOS to HSP90 and CaM . Direct 
interaction between CAV-1, CaM and HSP90 is evident in coprecipitation experiments 
from cells and, in experiments using purified proteins, eNOS forms a bridge between 
CAV-1 and HSP90 (Gratton et al., 2000). Thus, HSP90 influences eNOS activity in 
several ways.Another post-translational modification that regulates eNOS activity is 
protein phosphorylation (García-Cardeña et al., 1996). eNOS is phosphorylated primarily 
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on serine residues and, to a lesser extent, on tyrosine and threonine residues. The 
serine/threonine kinase Akt (protein kinase B) directly phosphorylates eNOS at Ser1177 
(human eNOS) and Ser1179 (bovine eNOS), which increases eNOS activity several-fold 
(Gallis et al., 1999). 
NO is also constitutively  produced and released from autonomic nerve terminals and 
endothelial cells in the corporal tissue. It has been also shown that NO mediate neurogenic 
non-cholinergic non-adrenergic (NANC) relaxation in human penile resistance arteries, in 
large penile arteries and in veins (Simonsen et al., 2002; Toda et al., 2005). In particular 
NO derives from its precursor, L-arginine, under catalytic action of NOS and it diffuses 
into smooth muscle cells where binds intracellular guanylate cyclase (Burnett et al., 1995; 
Burnett et al., 1997). This event induces the activation of guanylate cyclase that catalyzes  
conversion of guanosine triphosphate (GTP) to cGMP; this mediator then operates through 
a cGMP-dependent protein kinase to regulate the contractile state of the corporal smooth 
muscle (Hedlund et al., 2000). Indeed, in 2000 Minhas and co-workers demonstrated that 
cGMP inhibits the presynaptic release and contractile effects of norepinephrine (Minhas et 
al., 2000).  
NO, in corporal smooth muscle cells, also induced a relaxation which is independent of 
cGMP action. Gupta et al., in 1995, showed that NO stimulates Na+/K+-ATPase channels, 
resulting in direct hyperpolarization of the corporal smooth muscle cell, which prevents the 
opening of voltage-dependent calcium channels and thereby attenuates tissue contraction. 
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Figure 6: Diagrammatic representation of nitric oxide (NO) synthesis, regulation, and action in the 
penis. Constitutive formation of NO derives from its precursor, L-arginine, under the catalytic action of the 
NO synthase (NOS) isoforms nNOS and eNOS, respectively, on the basis of the cellular localizations of the 
enzyme to neurons and endothelial cells. Conventional signal transduction involving NO constitutively is 
characterized by messenger molecules that commonly activate NOS isoforms by signaling influx of calcium 
and its binding with calmodulin.  
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 Prostanoids 
It is well established that human corpus cavernosum can locally synthesize and 
metabolize several prostanoids (Miller and Morgan 1994; Anderson & Wagner  1995; 
Porst et al., 1996; Minhas et al., 2000). The effects of five primary active prostanoid 
metabolites, PGD, PGE, PGF, PGI, and thromboxane A2, are also mediated through 
specific receptors namely DP, EP, FP, IP and TP receptors. Prostanoid receptors are G-
protein coupled with different transduction systems (Coleman et al., 1994; Pierce et al., 
1995; Narumiya et al., 1999). PGF2α and thromboxane A2 may be involved in contraction 
of erectile tissue, stimulating FP and TP receptors and initiating phosphoinositide turnover. 
Indeed PGE1, stimulating EP receptor, induced relaxation of human corporal smooth 
muscle by hyperpolarization after activation of Ca2+-dependent potassium channel (Lee et 
al., 1999). Escrig et al., in 1999, showed that repeated PGE1 treatment enhances responses 
to nerve stimulation in the rat penis by up-regulating constitutive NOS isoforms (Escrig et 
al., 1999). 
Prostanoids exert their effects mainly through cAMP. In fact forskolin, which directly 
stimulates adenylate cyclase and consequently intracellular cAMP, significantly increases 
the production of cAMP by PGE1, which suggests a possible synergistic effect (Palmer et 
al., 1994; Traish et al., 1997a). Traish et al., also demonstrated that the augmentation of 
the forskolin-induced cAMP generation by PGE1 was mediated by EP receptors and more 
likely it could be ascribe to interactions between the adenylyl cyclase and G-proteins 
(Traish et al., 1997b). 
 
 Vasoactive intestinal polypeptide 
The human penis as well as animal one is richly supplied with nerves containing 
vasoactive intestinal polypeptide (VIP) (Dail et al., 1993). These nerves are densely 
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concentrated in the penis around the pudendal arteries and in erectile tissue but they are 
also present in vas deferens and epididymus (Polak et al., 1981). VIP has a potent 
vasorelaxant effect on human corpus cavernosum. The effects of VIP is also mediated 
through specific receptors namely DP, EP, FP, IP and TP receptors. VIP receptors are of 
two different types, 1 and 2, both linked via stimulatory G-protein to adenylyl cyclase 
(Fahrenkrug 1993; Harmar et al., 1998). The stimulatory effect of VIP on adenylyl cyclase 
leads to an increase in cAMP, which in turn activates cAMP-dependent protein kinase. In 
corporal tissue from human, rats and rabbits VIP increased cAMP concentrations without 
affecting the cGMP levels (Hedlund et al., 1995; Miller et al., 1995). VIP is a potent 
vasorelaxant of human corpus cavernosum at very low doses but it is not clear if VIP 
released from nerves is responsible for the relaxation of penile smooth muscle cells in vitro 
or in vivo (Andersson and Wagner 1995).  The effect of exogenous VIP was inhibited by 
VIP antiserum.  Adaikan et al., showed that intracavernous injection of VIP in human 
volunteers caused some degrees of penile enlargement but not erection in 5 of 7 subjects. 
Besides, VIP plasma levels measured in 12 patients with various types of erectile 
dysfunction (6 with psychogenic impotence, 2 with induratio penis, 4 with impotence of 
vascular origin) did not increase during pharmacologically induced erection in any patients 
treated with PGE1 (Adaikan et al. 1986a,b). In addition VIP concentrations in peripheral 
venous blood were similar to those detected in corpus cavernosal blood (Koehn et al., 
1993). These data suggested that VIP does not cause erection by itself but it could be 
acting in synergy with other vasodilatory agents. Nevetheless, a clinical study showed, that 
in healthy adult male volunteers there wasn’t any increase in VIP plasma levels neither in 
systemic nor in cavernous blood when the flaccid penis became rigid. Conversely, during 
penile detumescence mean cavernous VIP levels increased whereas VIP remained 
unaltered in systemic circulation (Becker et al., 2002). These findings highlight VIP as a 
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possible mediator in the mechanism of male sexual arousal, although its role in the penis 
physiology needs to be clearly addressed. 
 
 Hydrogen sulphide 
Hydrogen sulphide (H2S), the colourless gas with a strong odour of rotten eggs, was 
only known as a toxic environmental pollutant. About twenty years ago H2S has been 
proposed as gaseous neurotransmitter involved in physiological and/or pathological 
processes (Li et al., 2005; Zhong G et al., 2003; Bhatia et al., 2005). This gas is produced 
in many tissues, particularly in the brain, in the cardiovascular system, in the liver and in 
the kidney. It is synthesised from L-cysteine (L-cys) by cystathionine β-synthase (CBS) 
and cystathionine γ-liase (CSE), both pyridoxal-5’-phosphate-dependent enzyme. CBS and 
CSE have been detected in human and other mammalian cells and their expression is tissue 
specific (Levonen et al., 2000; Zhao et al., 2001). Recent studies demonstrated the 
involvement of H2S in erectile function in rodents and monkeys (Srilatha et al., 2007). In 
2008 d’Emmanuele di Villa Bianca et al. proved the involvement of L-cys/H2S pathway in 
penile erection in vivo. They showed that human penile tissues expressed CBS and CSE as 
both protein and mRNA, and that CSE modulates the L-cys/H2S pathway in peripheral 
cavernous nerves. In addition they demonstrated that human tissues can synthesize H2S 
from L-cys via catalytic actions of CBS and CSE. In this study it has been also revealed 
that NaHS (stable donor of H2S) and L-cys relaxed human corpus cavernosum strips in an 
endothelium-independent and concentration-dependent manner. Finally, in vivo studies 
performed on rats, they showed that intracavernous administration of NaHS caused a dose-
dependent increase in intracavernous pressure, implying that exogenous H2S can cause 
penile erection (d’Emmanuele di Villa Bianca et al., 2008). 
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1.3  Erectile dysfunction 
Erectile dysfunction (ED) is defined as the consistent or recurrent inability of a man to attain and/or 
maintain a penile erection sufficient for sexual activity (2nd International Consultation on Sexual 
Dysfunction-Paris, June 28th–July 1st, 2003). ED can be due to a number of different 
pathophysiological process. Already twenty years ago, Helen Kaplan estimated that 
erectile failure was psychogenic in 90% and organic in 10 % of cases. Today, the current 
opinion is that in most patients ED is of mixed aetiology that may be either predominantly 
psychogenic or organic.  In fact actually ED is classified into three different types: 
psychogenic (caused by psychological or emotional factors rather than physical ones), 
organic (caused by the inability of penile smooth muscle cells to relax) and mist (when 
there is a combination of both, organic and psychogenic ED).  
Recently, several clinical and epidemiological studies have been performed in order to 
define the risk factors for ED and they showed the possible role of age, obesity, smoking 
and cardiovascular diseases in the development of ED. These events can induce multiple 
disorders, including nerve damage, endothelial damage, alteration in receptor 
expression/function, or in the transduction pathways implicated in the relaxation and 
contraction of smooth muscle cells.  
 
1.3.1 Age 
The prevalence of ED increases significantly with age, as there are clear changes in the 
physiology of male sexual activity (Lunefeld et al., 2002; Seftel et al., 2003). Indeed, in 
the Massachusetts Male Aging Study (MMAS) 39% of men had some degree of ED at the 
age of 40 (Feldman et al., 1994). This prevalence gradually increased to reach 67% at the 
age of 70. The relevant age-related increase of ED prevalence is predominantly due to age 
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as a risk factor. In fact it is difficult to discriminate between aging and concomitant 
diseases.  
It is well known that aging cause alteration in anatomical structures. In fact changes of 
the smooth muscle cells component, elastic fibres, or collagen content provoke mechanical 
alteration of penis, reducing its elasticity and compliance.   
Aging can induce also alteration in the transduction pathways implicated in the penile 
physiology. In fact, Garban et al., (1995) found that the NOS activity decreased in penile 
tissue in senescent rats (Garban et al., 1995). In another study, NOS mRNA expression in 
old rats was found lower than in young ones (Dahiya et al., 1997). Instead in the aging 
rabbit, endothelium-dependent corpus cavenosum relaxation was attenuated; however, 
eNOS was up regulated both in vascular endothelium and corporal smooth muscle cells. 
These data suggest that erectile dysfunction in the aging rabbit cavernosum appears to be 
related to endothelial dysfunction and is characterized by eNOS up regulation and aberrant 
intracellular calcium fluxes (Haas et al., 1998). 
Besides, ED is often associated with other conditions that are common in aging men, 
and the most important involves the cardiovascular system.  
 
1.3.2 Lifestyle  
Several studies reported that lifestyle factors are frequently associated with ED and 
they include a sedentary life, and obesity, smoking and alcohol or drug abuse. 
 
a) Obesity 
An increase in body mass represents a significant risk factor involved in the 
development of ED.  
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In 1999 Chung et al., evaluated ED in 325 patients classified into two groups according 
to the body weight: <120% and >120% of the ideal body weight. They showed that in 
patients with obesity there was a significant decrease in the quality of erectile function. 
Furthermore, about 43% of obese patients presented a significantly increased prevalence of  
vascular risk factors, suggesting that obesity does impose a risk to vasculogenic impotence, 
promoting development of chronic vascular disease. A controlled study in obese men also 
revealed that increase of physical activity reduced the progression of  ED (Esposito et al., 
2004). In another large study, during five years, the incidence of ED was estimated in men 
aged 50, 60, 70 years residing in the city of Tampere or eleven surrounding  municipality  
in Finland. It has been demonstrated that there were not difference of ED according to the 
level of education, marital status, urban/rural place of residence and amounts of alcohol 
and coffee consumption, while obesity and current smoking significantly increased the 
incidence of ED (Shiri et al., 2004). 
 
a) Smoking  
Smoking is an important risk factor in the development of impotence (Mannino et al., 
1994). In 2000 Feldman et al., conduced a study based on Massachusetts Male Aging 
Study, in a random-sample cohort study. They investigated the relationship between 
baseline risk factors for coronary heart disease and subsequent ED, on the premise that 
subclinical arterial insufficiency might be manifested as ED. They showed that cigarette 
smoking at baseline almost doubled the likelihood of moderate or complete ED at follow 
up. Cigar smoking and passive exposure to cigarette smoke also significantly predicted 
incident ED, as overweight and a composite coronary risk score did. Weaker prospective 
associations were seen for hypertension and dietary intake of cholesterol and unsaturated 
fat (Feldman et al., 2000). In fact cigarette smoking has been considered an independent 
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risk factor in the development of atherosclerotic lesions in the internal pudendal and 
common penile arteries of young men with ED. In this study, evaluating the relationship 
between cigarette smoking and the atherosclerosis of the hypogastric-cavernous arterial 
bed, it has been showed that the atherosclerosis was significantly increased in patients that 
had been smoking for many years (Mannino et al., 1994). Smoking also has been 
associated with several changes at molecular level; in particular it causes an impaired 
penile flow. In rats passive smoking causes age-independent moderate systemic 
hypertension and marked decrease in penile NOS activity and nNOS content (Xie et al., 
1997).  
 
a) Alcohol or drug abuse 
Several classes of medications, recreational drugs and alcohol have been linked to the 
manifestation of ED. About alcohol, its primary action  is increasing blood volume, which 
in turn causes higher blood pressure. Thus, in theory, alcohol consumption should assist 
erection and not cause erectile dysfunction. Also, elevated quantity of alcohol operates as a 
sedative and may also help curb performance anxiety that is a major cause of ED in 
younger men. Even drugs and some medications exhibit their adverse events, like either 
central inhibitory neuroendocrine mechanisms and/or local neurovascular actions, or they 
have an impact on the hormonal (luteinizing hormone, testosterone and prolactin) and 
neurotransmitter pathways (serotoninergic, dopaminergic or adrenergic systems).   
 
1.3.3 Cardiovascular risk factors 
More than 20 years ago, it has been showed that chronic arterial disease, compromising 
the blood flow in the cavernous arteries, could be a significant cause of ED (Michal et al., 
1982). Heart disease and its associated risk factors, such as hypertension and low serum 
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high density lipoprotein cholesterol, are significantly correlated with ED (Feldman et al., 
2000).  Several studies suggest ED as a predictive factor for coronary disease (Shamloul et 
al., 2004; Billups et al., 2005). Vasculogenic impotence has been reported to be the first 
sign of a generalized arteriopathy. Muller et al. reported a very high incidence (85%) of 
cavernous artery insufficiency in a group of 117 hypertensive patients  (Muller et al., 
1991). In a rabbit model of atherosclerotic ED, it was shown that chronic cavernosal 
ischemia impaired not only the endothelium-, but also neurogenic-dependent corpus 
cavernosum relaxation and NOS activity (Azadzoi et al., 1998). Hypercholesterolemia also 
impaired endothelium mediated relaxation of rabbit corpus cavernosum smooth muscle 
(Azadzoi and Saenz de Tejada;  Azadzoi et al., 1998 ).  
 
1.3.4 Diabetes 
Several studies confirmed  the etiological role of diabetes in ED. In fact has been 
reported that ED develops in 35-75 % of diabetic patients (Hatzichristou et al., 1994) and it 
has been shown to occur three times more frequently in diabetic than in non diabetic 
subjects (Feldman et al., 1994). The cause is multifactorial, but it almost commonly 
reflects endothelial dysfunction and autonomic neuropathy (Saenz de Tejada et al., 1989). 
Penile NOS activity and content were reduced in rat models of both type I or II diabetes 
with ED (Vernet et al., 1995). However, in streptozotocin-induced diabetic rats, NOS 
binding increased (Sullivan et al., 1996), and NOS activity in penile tissue was 
significantly higher than in controls, despite a significant drop of mating behaviour and 
indications of defective erectile potency (Elabbady et al., 1995). It has also been showed 
that the nocturnal penile tumescence was altered in diabetic patients, indicating a change in 
normal physiology function. In 1990, Blanco et al., demonstrated that there was a 
functional penile neuropathic condition of the cholinergic nerves in the corpus cavernosum 
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of diabetic patients and concluded that ED in diabetes may be a secondary effect of a 
neuropathic condition. Molecular studies on human penile tissue have also shown that the 
diabetic ED is related to the effects of advanced glycation end products and NO formation 
(Seftel et al., 1997). In fact, advanced glycation end products were found to be more 
elevated in the penile tissue, but not in serum, in diabetic patients than healthy patients. 
However the involvement of advanced glycation end products has been demonstrated by 
the high levels in the tunica and corpus cavernosum of diabetic patients (Seftel et al., 
1997). 
There is only one study about the possible role of androgens in diabetics. This study 
demonstrated that in diabetics there was an unchanged level of luteinizing hormone but 
there was a decrease in testosterone levels accompanied by an increase in testosterone 
binding globulin capacity and then a markedly decrease of the apparent free testosterone 
concentration (Ando et al., 1984). Finally it has been showed that an impairment of VIP-
releasing innervations in penile tissue may be an important factor in the development of 
impotence in diabetes (Crowe et al., 1983). 
 
1.3.5 Medical disorder 
Several systemic diseases are associated with ED.  
 
a) Neurologic disease 
Multiple neurologic diseases can be the cause of ED. As well known, the sexual 
stimulation takes place in the brain: the higher cortex, the limbic and paralimbic regions 
and other subcortical regions participate in motivational, motor, or emotional sexual 
stimulation. Impulses from brain to genitalia are carried by either lumbar and sacral spinal 
roots and autonomic system. Lesions in these areas may result in ED. Indeed various 
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neurological conditions are associated with ED: multiple sclerosis, temporal lobe epilepsy, 
stroke, Parkinson and Alzheimer’s disease, all disorders at brain level, or spinal cord 
injuries (Giuliano et al., 2000; Saenz de Tejada et al., 2005; Goldestein et al., 1982). 
Peripheral neurologic disorders related to ED include afferent neuropathies, such as dorsal 
penile affections (diabetic neuropathy),  or afferent lesions, or lesions of the cavernous 
nerves after radical pelvic surgery. 
 
b) Chronic renal failure 
More than 50% of men with chronic renal failure is affected by ED. This process is 
multifactorial and includes hyperprolactinemia, hypertension, smooth muscle dysfunction 
secondary to circulating toxins, neuropathy and atherosclerosis (Nogues et al., 1991). In 
patients requiring dialysis, occlusion of cavernous arteries and veno-occlusive dysfunction 
were found in 78% and 90% of patients respectively (Kaufman et al., 1994). 
 
c) Respiratory disease 
Up to 30% of men with chronic obstructive pulmonary disease suffer of ED. The 
pulmonary disease, and consequently hypoxia, may represent the primary etiologic factor 
in these cases (Fletcher et al., 1982). Other authors suggested an association between ED 
and sleep syndrome, as well as sleep apnoea (Moreland et al., 1999). 
 
d) Hepatic insufficiency 
ED has been associated with chronic liver dysfunction in more than 50% of case and it 
may reach up to 75% in alcoholic liver cirrhosis (Cornely et al., 1984). Zonszein et al., 
hypothesizing a mechanism, suggested that ED in hepatic failure can be caused by 
hyperprolactinemia, by a decrease of testosterone due to an increased sex hormone binding 
globuline synthesis, and by elevated level of estrogens (Zonszein et al., 1995). 
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 1.3.6 Other man dysfunctions 
a) Peyronie’s disease 
Peyronie’s disease is characterized by the formation of a fibrous nodule in the tunica 
albuginea. These plaques impede tunical expansion during erection, resulting in penile 
bending. Many possible etiological factors have been suggested but penile trauma appears 
to be the most likely. Trauma to the penis move up an inflammatory process that stimulates 
the fibroblast to produce collagen and then the plaque. 
 
b) Priapism 
Priapism is defined as unwanted erection not associated with sexual desire or 
stimulation. It is generally secondary to blunt trauma of the penis or perineum. Two 
different types of priapism can be distinguished: ischemic, or no flow priapism, and high 
flow priapism. The former is characterized by a reduction or loss of the normal venous 
outflow from the penis; this event leads to a failure of detumescence, increasing anoxia, 
necrosis and fibrosis in the tissue. The latter, much  less common, causes an abnormal high 
arterial blood flow into the penis.  
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1.4  Diagnosis of erectile dysfunction 
Sexual dysfunction may stem from various causes, including physiological or 
relationship factors, medical illness or medications taken for  illnesses. Often such factors 
work in concert. For this reason, the first and most important step in the treatment of ED is 
represented by examination and diagnosis. In fact the doctor evaluates two paramount 
factor contributing toward the successful diagnosis of ED: history and physical exam. At 
first the patient may ask about his personal history (about his past and present medical 
problems, about medications or drugs being used, and about any history of psychological 
problems, including stress, anxiety, or depression) and then about his sexual history (the 
nature of the onset of the dysfunction, the frequency, quality, and duration of any erections, 
and whether they occur at night or in the morning; the specific circumstances when erectile 
dysfunction occurred; the patient's motivation for and expectations of treatment; whether 
problems exist in the current relationship). Instead the physical exam include examination 
of the genital area and a digital rectal examination to check for prostate abnormalities.  
 
1.4.1  Questionnaires 
Questionnaires are not mandatory in the evaluation of ED, but they often serve as an 
important adjunct to the proper diagnosis. There are a variety of general questionnaires in 
use such as Sexual Health Inventory for Men (SHIM), International Index of Erectile 
Function (IIEF), Sexual Encounter Profile (SEP) and Male Sexual Health Questionnaire 
(MSHQ). All questionnaire present simple, straightforward, yet comprehensive question 
about erectile activity over 3-6 month time frame (Cappelleri et al., 2005; Rosen 1997; 
Rosen 2004). IIEF and SEP are currently the most used questionnaire to measure of 
efficacy in any study evaluating ED treatments.  
 
Introduction: physiology and pathophisiology of erectile function  
 
 34 
1.4.2  Physical Examination 
The physical examination represents an essential component of sexual dysfunction 
evaluation. In most cases, this examination does not identify the aetiology or cause of ED, 
but will help in formulation of diagnosis. The physical examination includes a general 
screening for medical risk factors or disorders, with specific attention to cardiovascular, 
neurologic and genitalia system (Tab. 1) 
 
 
Tab. 1: Brief points to cover in the physical examination of the male with ED. 
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1.4.3  Laboratory test 
Routinely laboratory tests include, first of all, blood sugar and fasting lipid profile, 
PSA screening and urine analysis (glucose, ketones and proteinuria). Then hormones 
associated with sexual desire are monitored: free testosterone, testosterone, prolactin and 
dehydroepiandrosterone (DHEAS) may be part of ED evaluation. Luteinizing hormone 
(LH), follicle stimulating hormone (FSH) and sex hormone binding protein (SHBG) are 
determined for further differential diagnosis in the case of low testosterone values, to 
ascertain primary or secondary hypogonadism. Instead estradiol, growth hormone and 
thyroid parameters are determined in individual cases to diagnose further hormonal 
deficits.    
 
1.4.4  Invasive tests 
These tests were used since 1980s. Now invasive tests have been surmounted by 
previously mentioned tests. The invasive tests more used are: 
 
 Pharmacological testing 
Intracavernous injection of a vasodilator (generally PGE1) is used to differentiate 
vasculogenic to non-vasculogenic ED. In fact positive results of this test only demonstrate 
the integrity of veno-occlusive mechanism (Figure 7). If a full erection is not seen within 
ten minutes, or if the erection lasts only a short time, the patients is allowed to stimulate 
himself. Failure after stimulation is considered to be a good indicator of the presence of 
vasculogenic ED (Muhlhall et al., 1997) (Figure 7).  
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Figure 7: Intracavernous injection of  vasodilator drugs. 
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 Color Doppler Imaging (CDI) 
After intracavernous injection of PGE1 the penis can be scanned by color duplex 
ultrasonograpy (Figure 8) (Connolly et al. 1996). The velocity of blood flow in 
intracavernous artery during diastolic and systolic phase is monitored within five minutes 
of injection and repeated frequently.  
Doppler is a good technique to make the differential diagnosis of no flow and high 
flow priapism. 
 
Figure 8: Color Doppler Imaging (CDI). 
(A) Arterial waveform in the penis recorded by color duplex ultrasonography showing standard parameters 
measured (PFV, peak flow velocity; EDV, end-diastolic velocity). (B) Normal vascular response: PFV >35 
cm/s, EDV nil. (C) Arterial insufficiency: PFV <25 cm/s. (D) Veno-occlusive dysfunction: 20 minutes after 
injection and sexual stimulation. PFV >35 cm/s and EDV >5 cm/s. 
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 Nocturnal penile tumescence (NPT) 
The NPT test checks whether a man is having normal erections during sleep. Most men 
have 3 to 5 full erections during deep (rapid eye movement, or REM) sleep. Men who do 
not have erections because of psychological problems can still have erections during deep 
sleep. Occasionally, some sleep problems or serious depression can prevent these normal 
nighttime (nocturnal) erections. An electronic monitoring device is more expensive than 
using the snap gauge, but it is more accurate and gives more detailed information about 
erections during sleep (Figure 9 A,B). This device records how many, how long, and how 
rigid the erections are during sleep. If good erections occur during sleep, the cause of the 
erection problems probably is not physical. 
 
 
 
Figure 9: (A) The Rigiscan: a device for the evaluation of nocturnal penile tumescence. The apparatus 
records through the ring’s rigidity at the base and tip of the penis. (B)  (a) A Rigiscan trace from a nocturnal 
penile tumescence test from a normal healthy volunteer. The trace shown refers to 1 night. Four erective 
episodes are visible, with good duration and excellent rigidity both at base and tip of the penis. (b) A 
Rigiscan trace from a nocturnal penile tumescence test from a severe ED patient. The trace shown is a 1 night 
record. The absence of erective episodes is suggestive of organic erectile dysfunction. 
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 Bulbocavernous reflex Latency Times (BCR) and Somatosensory Evoked 
Potentials (SSEP) 
This method is used to prove the integrity of somatic penile innervations. A ring 
electrode on the distal shaft of the penis is used to apply impulses via a constant current 
stimulator, and the reflex latency time is measured via the needle electrodes placed in the 
bulbocavernous muscle. 
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1.5  Treatment of erectile dysfunction 
Pharmacological therapies can acts centrally or peripherally on the penis, or both. 
Once, pharmacologic treatment of ED was limited to a few substances, most of which 
had to be injected directly into the corpora cavernosa.  
 
1.5.1  Intracorporal pharmacological therapy 
Three drugs have been used most frequently: PGE1 (the most widely used), papaverine 
and phentolamine. 
 
  Papaverine 
Papaverin, a non oppioid derivate from Papaver Somniferum, was the first drug to be 
used. As a good smooth muscle relaxant, in vitro has been showed that papaverine evokes 
relaxation of human corpus cavernosum strips, penile arteries cavernous sinusoids, and 
penile veins (Virag et al. 1984).    
At cellular level papaverin is a non-specific phosphodiesterase inhibitor that causes 
increase in intracellular cGMP and cAMP, resulting in a fall in the cytoplasmatic calcium 
concentration leading to smooth muscle relaxation and penile erection (Figure 10). 
 
 
Figure 10:  Molecular mechanism of papaverine action. 
It inhibits both cAMP and cGMP resulting in smooth muscle relaxation. 
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 Prostaglandin E1 (PGE1) 
The effect of PGE1 on the human corpus cavernosum was described for the first time 
in 1975 by Karim and Adaikan who demonstrated its effect in HCC in vitro (Karim & 
Adaikan, 1975). PGE1 acts primarily via specific receptor on the surface of the smooth 
muscle cell to stimulate the enzyme adenylate cyclase. This enzyme converts adenosine 
triphosphate (ATP) into cyclic adenosine monophosphate (cAMP) (Lin, 1995). Therefore 
injection of PGE1 causes a rise in intracellular cAMP, causing a fall in intracellular 
calcium and subsequently smooth muscle relaxation (Lee et al., 1999) (Figure 11).  
PGE1 was also shown to suppress the collagen synthesis by TGF-β1 in cultured HCC, 
suggesting that PGE1 may play a key role in modulation/prevention of collagen synthesis 
with subsequent fibrosis of corpus cavernosum (Moreland et al., 2003). 
 
 
Figure 11: Molecular mechanism of PGE1 action.  
It stimulate adenylate cyclase causing a fall in intracellular calcium and thus smooth muscle relaxation. 
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  Phentolamine 
Phentolamine is a competitive non-selected α1 and α2-adrenoceptor blocker that acts both 
on presynaptic and postsynaptic α-adrenoceptors. In addition it acts opening potassium 
channel, antagonizing endothelin and causing a stimulatory effect on NO synthase (Gupta 
et al., 1998; Traish et al., 1998) (Figure 12). Phentolamine when injected alone has a 
modest therapeutic effect; however, it has a synergistic action when combined with drugs 
such as papaverine and PGE1. 
 
 
 
 
Figure 12: Molecular mechanism of phentolamine action. 
As inhibitor of both α1 and α2 adrenoceptors, it blocks the tonic sympathetic neuronal activity which 
normally produces smooth muscle contraction. 
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1.5.2.   Oral therapy 
The first oral therapy was characterized by drugs containing yohimbine, and in some 
cases the serotonin re-uptake inhibitor trazodone (Figure 13).  Instead new generation of 
drugs acts directly on smooth muscle cells inhibiting PDE5. 
 
 
 
Figure 13: Centrally and peripherally acting drugs. 
(A) Apomorphine acts centrally on D2 dopaminergic receptors in the hypothalamus. Yohimbine is an α2 
adrenergic blocker that acts centrally and peripherally. Both decrease the penile smooth muscle intracellular 
Ca++ inducing smooth muscle relaxation and promoting erection. (B) PDE5 inhibitors decrease the 
degradation of cGMP following in smooth muscle relaxation and enhancing erection.  
 
 
 
 
B A 
Introduction: physiology and pathophisiology of erectile function  
 
 44 
 Yhohimbine 
Yohimbine is an alkaloid from the bark of Coryanthe johimbe K.Schum, of Rubiacee 
family. It is a central α2-adrenoceptor blocker and its activity being 50-100 times higher on 
presynaptic receptors than on postsynaptic ones (Ernst et al., 1998).  It has a peripheral 
action acting on α2-receptor of the penile arteries and on presynaptic α2-adrenoceptor, 
which are localized on α1-adrenoceptor of sympathetic nerve endings (Saenz de Tejada, 
1995). Therefore yohimbine facilitates erection at central level because acting on α2-
adrenoceptors inhibits erection-suppressing impulses mediated by sympathetic α1-
adrenoceptor. Instead, on penile tissue it inhibits presinaptically α1-adrenoceptor activity 
and facilitates the relaxation of smooth muscle cells. In addition, in 2005, d’Emmanuele di 
Villa Bianca et al. showed that apomorphine has a peripheral relaxant direct effect as well 
as an antiadrenergic activity on HCC strips. Since HCC possesses more D1-like (D1 and 
D5) than D2-like (D2, D3 and D4) receptors, while both D1- and D2-like receptors are 
mainly localized on smooth muscle cells, the relaxant activity is most probably mediated 
by D1-like receptor partially through NO release from endotheliumn (d’Emmanuele di 
Villa Bianca et al., 2005). 
 
 Apomorphine 
The activity of apomorphine was first known for its effect at central level in 
Parkinson’s disease. Apomorphine is a central dopamine receptor agonist with effect on D1 
and D2 receptors. Predominant sites of its action are located in the paraventricular nucleus, 
stria terminalis, medial pre-optic area and amygdaloid nucleus (Chen et al., 1996). 
Apomorphine induced-erections are both testosterone and NO dependent. (Chen et al., 
1997; Melis et al., 1993). 
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 PDE5 inhibitors 
Actually PDE5 inhibitors are the reference class in ED oral therapy. They enhance 
penile smooth muscle relaxation and penile erection in response to sexual stimulation. 
These drugs, inhibiting PDE5, decreases the degradation of cGMP. The augmentation of 
cGMP concentration increases smooth muscle cells relaxation which dilates sinusoids 
resulting in increased blood flow and enhancing erection.  
 
1.5.3. Surgical treatment 
 Vascular surgery 
The vascular surgery is only indicated in high selected patients to correct penile arterial 
insufficiency, to correct venous leakage due to veno-occlusive dysfunction by reducing 
venous outflow during erection, or both, when the two pathologies coexist.  
 
 Penile prostheses 
Penile prostheses are the last therapy when all other means have failed or are 
contraindicated. The intervention consist in an implantation of a pair of flexible silicon 
cylinders in the corpora cavernosa. The cylinder are connected to a pump device placed in 
the scrotum that can inflate or deflate the prosthesis.  
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 1.6  Aim of studies 
Erectile dysfunction (ED), defined as the consistent or recurrent inability of a man to 
attain and/or maintain a penile erection sufficient for sexual activity (2nd International 
Consultation on Sexual Dysfunction-Paris, June 28th–July 1st, 2003), can be caused by a 
number of different pathophysiological process. For these reasons, the present study can be 
divided into three steps in which we have analyzed various aspects of physiology and 
physiopathology of erectile function to give a contribution in the development  of novel 
therapeutic approaches for treatment of ED and sexual arousal disorders. 
We have first analyzed man dysfunctions that develop into ED, and in particular 
Peyroenie’s disease (PD). PD is a connective tissue disorder involving the growth of 
fibrous plaques in the tunica albuginea of the penis with curvature and distortion, causing 
penile pain and erectile dysfunction during the erection (Gelbard et al., 1999). PD consists  
in a molecular and physiopathological disorder that is poorly understood mainly because of 
to the lack of an appropriate animal model. For this reason in the first part of this study we 
have focused on the characterization of a new model of PD naturally occurring in the 
mouse strain Tight skin (Tsk). Tsk mice, for their mutation of fibrillin I gene, has been 
previously proposed as a model of scleroderma and fibrosis (Jimenenz  et al., 1984; Green 
et al., 1976).   
PD represent a particular case of ED. Indeed, it is now widely accepted that ED is 
predominantly a vascular disease. In particular the erectile function is regulated by a 
balance between vasorelaxant and vasoconstrictor factors.  The breaking of this balance 
can be cause of ED.  To identify new pathways involved in penile erection, that could be 
target for new therapies, our attention has been placed on urotensin II, an endogenous 
peptide previously described as an important vasoactive peptide (Ames et al., 1999; Bottril 
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et al., 2000). We have evaluated if and how urotensin II pathway could be involved in 
penile erection.  
Finally we have analyzed various methods for ED diagnosis. ED and its grade and the 
efficacy of ED treatment, are actually evaluated by medical questionnaire scores, a non-
objective method. The unique objective and non-invasive method is the rigiscan, but it is 
poorly reproducible. The most used therapy in ED treatment is actually represented by 
PDE5 inhibitors which, inhibiting PDE5, increase the action of cGMP and thereby enhance 
penile cavernosum and vascular smooth muscle relaxation and erection. The target of these 
drugs, PDE5, has been founded in other tissues than the penis, such as vascular smooth 
muscle, smooth muscle of the gastrointestinal tract and in platelets. For these reasons we 
have assessed if platelet cGMP could act as a biomarker of PDE5 activity in ED clinical 
studies. 
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2.1 Peyronie’s disease 
 
Peyronie’s disease (PD), or induratio penis plastica, is an inflammatory condition 
characterized by connective tissue disorder for the formation of  fibrous plaques, nodules 
within the tunica albuginea (Gelbard et al., 1993; Devine et al., 1988)  
The formation of these plaques alters penile anatomy, impeding expansion of the tunica 
albuginea during erection, resulting in penile binding. (Figure 14) (Bevilacqua et al., 2000 
a; b). 
 
 
 
 
Figure 14: A fibrous plaque of Peyronie's disease on the top portion 
of shaft.  Bending of penis upward is in response to presence of scar 
that prevents full expansion 
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This condition affects 5-9 % of the men (Vernet et al., 2005). Subsequent to the 
progression of the PD, and than to inflammation and cessation of the pain, the plaques may 
ossify in 15-25 % of cases (Vernet et al., 2005). 
Peyronie’s patients can be classified into three categories: (1) patients with 
asymptomatic plaques, (2) patients with plaques that exacerbate penile bending, (3) 
patients whose Peyronie’s disease is associated with ED (Krane, 1997). 
The mechanisms of the development of this disease are still unclear for the absence of 
an appropriate animal model. In fact, the animal model actually used have been obtained 
by injection of  beta transforming growth factor (TGFβ) (El-Sakka et al., 1997; El-Sakka et 
al., 1998) or fibrin (Davila et al., 2003) in the rat tunica albuginea. Unluckily, these acute 
animal models do not reflect the natural course of human disease.  
The aetiopathogenesis of PD is unclear. In fact in 1957, Furey  initially suggested (and 
most investigators now concur) that minor sexual trauma is the major cause of PD (Furey, 
1957). Afterward it has been demonstrated that repetitive microtrauma during intercourse 
may be the initiating factor, causing a localized autoimmune response in susceptible 
individuals (Mulhall, 2003; Jarow & Lowe, 1997). PD is now considered a multifactorial 
pathology based on the interaction of a genetic predisposition, trauma and tissue 
inflammation (Bevilacqua et al., 2000 a,b). Cytokine (particularly TGFβ and platelet-
derived growth factor (PDGF)) dysregulation and overexpression, production of free 
radicals (ROS), and ultimately excessive extracellular matrix deposition leads to plaque 
formation (Mulhall,  2003). At the present time pharmacotherapy has not been effective or 
widely accepted, and surgery to either remove the plaque or insert penile prostheses 
remains the mainstay of the treatment.  
We have looked for  a spontaneous animal model that may mirror the natural history of 
human PD. 
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2.2 Materials and methods 
 
2.2.1   Animals 
About twenty years ago Jacson Laboratory (Bar Harbor, ME) obtained male Tsk 
(B6.Cg-Fbn1Tsk+/+ Pldnpa/J) and female pallid (B6.Cg-Pldnpa/J) mice. For our experiment 
these animals were from Siena colony, obtained using Tsk mice and homozygous pallid 
female, because Tsk females were poor breeders. In this study male congenic C57B1/6J 
wild type (WT) mice served as controls. All the animal analyzed had no sexual experiences 
and were housed in groups of two to four in macrolon cages at room temperature (22-
24°C), with relative humidity (40-50%) and with food and water ad libitum.   
 
2.2.2  Histology 
Male Tsk mice were monitored for about two years and sacrificed at different ages, 2, 
4, 6, 8, 10, 12, 24 months (n= 8 for each groups). The penis of each animal was excised 
and fixed in buffered fomalin (5%) for 24 hours. All tissues were than dehydrated, cleared 
in toluene and embedded in paraffin. Finally trasversal section (6µm) were cut and stained 
with hematoxylin/eosin and Masson’s trichrome stain. 
 
2.2.3 Biochemical assay for hydroxyproline 
To determine tissue collagen, 6 penises from each animal group, at various ages, were 
weighed, homogenised in 5% TCA (1:9, w:v) and centrifuged for 10 min at 4000 × g. The 
pellet was then washed twice with distilled water and hydrolyzed for 16 h at 130 °C in 6N 
HCl. The pH of the samples was adjusted to 6.0 by adding 10N and then 0.1N sodium 
hydroxide. Distilled water was added to a final volume of 1.2 ml. Hydroxyproline was then 
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determined in tissue hydrolysates according to the method of Kivirikko et al. and data were 
expressed as µg/penis (Kivirikko et al., 1967). 
 
2.2.4 Immunohistochemistry of TGFβ, type I and type II collagen 
To evaluate the presence of TGFβ the penis of mice of each group were stained by 
immunoperoxidase method. The tissues were fixed in formalin and cut in section of about 
6 µm. Tissue sections were pre-treated with 3% hydrogen peroxidise for eliminating 
endogenous peroxidase activity. The samples were heated in a microwave for 20 minutes 
in citrate buffer of pH 6.0, and than allowed to cool slowly to room temperature for 
restoring immunoreactivity to tissue antigens retrieval. All the sections were incubated 
with 3% bovine serum albumin for 30 minutes at room temperature to block non-specific 
antibody binding. They were incubated overnight at 4°C with the primary antibody (Ab) 
(dilution 1:20), rabbit polyclonal Ab to mouse TGFβ. To determine type I collagen, the 
section slices were rinsed and incubated with goat polyclonal Ab to type I collagen 
(diluition 1:20). To detect type II collagen, instead, samples were incubated with rabbit 
polyclonal Ab to type II collagen (diluition 1:200).  
For TGF-β and type II collagen, the section slices were rinsed and incubated with 
sheep anti-rabbit IgG for 30 min at room temperature. For type I collagen, the section 
slices were rinsed and incubated with rabbit anti-goat IgG for 30 min at room temperature. 
The staining was revealed by adding peroxidase–antiperoxidase complex, prepared from 
rabbit (or goat) serum. Detection was accomplished by incubating in diamino-benzidine 
freshly dissolved in 0.03% H2O2 in 50 mM Tris-HCl pH 7.6 as negative control for the 
immunostaining the primary antibodies were replaced by non-immunised rabbit (or goat) 
serum. The sections were counterstained with ematoxilyn. 
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2.2.5 RNA isolation and cDNA synthesis 
Total RNA was extracted from 6 mouse penises, at different ages, using TRi Reagent , 
according to the manufacturer's instructions. RNA was resuspended in RT-PCR Grade 
Water and the amount and purity of RNA was quantified spectrophotometrically by 
measuring the optical density at 260 and 280 nm. Integrity was checked by agarose gel 
electrophoresis. 
Two micrograms of total RNA was treated with TURBO DNAse for 30 min (TURBO 
DNA-free kit) and reverse transcribed using the RETROscript kit according to the 
manufacturer's instructions. Two hundredths of the final volume of reverse transcription 
was used for real-time RT-PCR 
 
2.2.6  Quantitative Real Time PCR for iNOS and TGFβ 
For iNOS we performed the amplification using Pre-made Assay  in a 7500 abi 
Thermal Cycler. The amplification for TGFβ, instead, was done by Taqman chemistry 
using probes, primers and cycling condition previous described by Overbergh. (Overbergh 
et al., 1999). 
 
2.2.7  Real Time PCR for collagens, PDGF 
Real-time RT-PCR was performed in triplicate for each sample on the MJ Opticon 
Monitor 2 with specific locked nucleic acid (LNA) probes from the Mouse Universal 
Probe Library Set. Primers were designed by using the free online ProbeFinder software 
(available at the Universal ProbeLibrary Assay Design Center: 
www.universalprobelibrary.com) that shows a pair of specific primers for each probe from 
the Universal ProbeLibrary set (see Table 2). The combination of primers and probes 
provides specific amplification and detection of the target sequence in the sample. PCR 
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reactions were performed in a volume of 25 µl and contained 12.5 µl of FastStart TaqMan 
Probe Master, 300 nM forward and reverse primers, 200 nM UPL probes and 5 µl of 
cDNA.  
Reactions were incubated at 95 °C for 10 min and then amplified for 40 cycles, each 
cycle comprised of an incubation step at 94 °C for 15 s followed by 60 °C for 1 min. 
The real-time RT-PCR assay included a no-template control and a standard curve of 
four serial dilution points (in steps of 10-fold) of each of the test cDNAs. 
The analysis of the results was based on the comparative Ct method (∆∆Ct) in which 
Ct represents the cycle number at which the fluorescent signal, associated with an 
exponential increase in PCR products, crosses a given threshold. The average of the target 
gene was normalized to 18S rRNA as the endogenous housekeeping gene (Winer et al., 
1999). 
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Transcript 
 
Primer forward reverse 
 
Probe# 
 
18S (m11188.1) Forward 5′-aaatcagttatggttcctttggtc-3′ 55 
 Reverse 5′-gctctagaattaccacagttatccaa-3′  
 
NOS-2 (NM010927) Forward 5′-ctttgccacggacgagac-3′ 13 
 Reverse 5′-tcattgtactctgagggctgac-3′  
 
Col1a1 (NM007742.2) Forward 5′-catgttcagctttgtggacct-3′ 15 
 Reverse 5′-gcagctgacttcagggatgt-3′  
 
Col3a1 (NM009930.1) Forward 5′-tcccctggaatctgtgaatc-3′ 49 
 Reverse 5′-tgagtcgaattggggaga-3′  
 
Pdgfb (NM011057.3) Forward 5′-cggcctgtgactagaagtcc-3′ 32 
 Reverse 5′-gagcttgaggcgtcttgg-3′  
 
Pdgfrb (NM008809.1) Forward 5′-tcaagctgcaggtcaatgtc-3′ 67 
 Reverse 5′-ccattggcagggtgactc-3′  
 
Pdgfa (NM008808.2) Forward 5′-ccagcgactcttggagataga-3′ 73 
 Reverse 5′-gggctctcaggcttgtctc-3′  
 
Pdgfra (NM011058.1) Forward 5′-gtcgttgacctgcagtgga-3′ 80 
 Reverse 5′-ccagcatggtgatacctttgt-3′  
 
Tgfb1 (NM011577.1) Forward 5′-tggagcaacatgtggaactc-3′ 72 
 Reverse 5′-gtcagcagccggttacca-3′  
Tab 2. Primers Sequence and Probe Catalog Number 
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2.2.8 Statistical analysis 
Data are presented as mean ± standard deviation. The significance between groups was 
calculated using one-way analysis of variance. A p value less than 0.05 was considered 
significant. 
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2.3   Results 
 
2.3.1 Macroscopic morphologic analysis 
The Tsk mice were monitored for about two years and sacrificed at different ages to 
evaluate the development and progression of pathology.  
The gross morphology of the penis at the age of 2 months (Figure 15 A), 6 months 
(Figure 15 B), 8 months (Figure 15 C) and 12 months (Figure 15 D) is reported in Figure 
15. 
As can be seen there was an increase of fibrotic plaque with age. The disease in Tsk 
mice slowly developed reaching the maximum at 12 months. No further progression was 
observed from 12-13 months onwards. 
   Instead we have obtained different results from the penis of male congenic C57B1/6J 
wild type that showed a normal appearance at different age (Figure 15 E,F). 
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Figure 15: Gross anatomy of the Tsk mouse penis at 2 (A), 6 (B), 8 (C) and 12 (D) months 
of age. The penises from 2 month-old mice show a normal appearance (A). The white areas in 
(B), (C) and (D) are fibrotic  hypovascularized segments in the distal part of the penis. Fibrosis 
is appreciable from 6 months of age (B) onwards and  progressively increases at 8 (C) and 12 
(D) months of age. The latter group of mice (D) shows an extensive fibrosis and bending of the 
penis. The penises of 2 (E) and 12 month-old C57Bl/6 mice (F) show a normal appearance. 
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2.3.2  Histopathological  analysis 
The histopathological studies were performed on penis tissues at different ages.  
As can be seen in Figure 16 A, there was a normal appearance of the tunica 
albuginea in the penis of mice sacrificed at two months. 
 At six months of age, instead, the thickened of the inner layer bundles and the 
presence of inflammatory infiltrate of mononucleated cells in several areas, caused 
an evident disorganization and disassociation of the outer layer bundles (Figure 16 
B). 
 In eight month-old Tsk mice the inner layers bundles of the tunica were 
markedly thickened and diffused areas of chondroid metaplasia were usually 
detectable (Figure 16 C).  
These characteristics were more evident at twelve months of age when 
irregularly shaped and homogenous fibrous plaques were associated with areas of 
hyalinization, chondroid metaplasia or heterotopic ossification (Figure 16 D).  
 The sections of penis were stained by Masson’s trichrome (Figure 17)  
The penis tissue slides from two month old Tsk mice showed a normal amount 
and distribution of elastic and collagen fibres in the tunica albuginea (Figure 17 A).  
At six months there was an increase of deposition of collagen bundles thickening 
the tunica albuginea (Figure 17 B).  
The penis tissue slides from eight month old mice give us and idea about a 
development of pathological condition. In fact the smooth muscle structures in the 
pillars were not evident and the bundles appeared disrupted and dissociated (Figure 
17 C). 
These lesion is maximal in the penis of mice at twelve moths. In these tissues 
plaques were similar to those observed in the human Peyronie’s disease. This 
pathological phase is characterized by an excessive collagen accumulation, disrupted 
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collagen bundles and areas of heterotopic ossification with bone mineralization 
(Figure 17 D). 
 
 
 
 
 
Figure 16: Histopathological steps in the development of PD-like lesions in Tsk mice. 
(A) Normal appearance of the TA at 2 months of age. In this transverse section, note the fine circularly 
oriented bundles of the inner layer of the Tunica (arrowhead), which surround and penetrate the cavernous 
tissue. The outer layer bundles are longitudinal (arrow). (B) Longitudinal section of the TA at 6 months of 
age. The outer layer bundles are disorganized and disassociated (arrow). The inner layer bundles are 
thickened and an inflammatory infiltrate of mononucleated cells is present in several areas. (C) Longitudinal 
section of the TA at 8 months of age. The inner layer bundles of the Tunica are thickened and show diffused 
areas of chondroid metaplasia, which extend into the corpus (arrowhead). The outer bundles are disorganized 
and disassociated (arrow). (D) Transverse section of the TA at 12 months of age. The inner layer bundles of 
the Tunica are greatly thickened and form irregular homogeneous plates (asterisk) or nodules. 
 
 
 
 
(D) 
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Figure 17: Histopathological steps in the development of PD-like lesions in Tsk mice. 
 (A) Section of a TA with a normal appearance in a 2 month-old Tsk mouse. The intracavernosal pillars 
extending from the inner layer of the Tunica are composed of smooth muscle structures that intermingle with 
connective tissue (arrowhead) in which elastic and collagen fibers are intertwined. (B) Section of the TA in a 
6 month-old Tsk mouse. The Tunica is thickened due to the increased deposition of collagen bundles. (C) 
Section of the TA in a 8 month-old Tsk mouse, disrupted and disassociated collagen bundles (arrow) are 
present. The smooth muscle structures in the pillars are not evident. (D) Section of the TA in a 12 month-old 
Tsk mouse. Plaque, similar to that characterizing human Peyronie’s disease, is present in the tunica albuginea 
of the corpora cavernosa (asterisk). 
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2.3.3  Biochemical assay for hydroxyproline 
The results of biochemical analysis of the total penis collagen are reported as 
hydroxyproline (HO-proline) for eight and twelve months old for both wild type and Tsk 
(Figure 18 A) and as mRNA for collagen I and III in six, eight, ten and twelve months old 
Tsk mice (Figure 18 B). 
  In the panel A the values are expressed as percent of increase in HO-proline in respect to 
two months old mice because no difference in tissue HO-proline content was observed 
between the penis of C57B1/6J wild type and Tsk mice at two months of age. At eight 
months of age penile tissues of Tsk mice showed an average of 50% (p<0.01) and 34% 
(p<0.01) higher content in HO-proline than the penis of two months old Tsk mice 
(265.8±17.2 µg/penis) and eight months old WT mice (320.9±24.6 µg/penis), respectively. 
At twelve months of age the penis of Tsk mice showed a mean content in HO-proline 
(434.7±20.4 µg/penis), which was 43% (p<0.01) greater than that of WT mice.  
RT-PCR for type I and II collagens in penile tissue showed an increase of collagen 
content in eight months old Tsk mice (Figure 18 B). This effect was preceded, at six 
months of age, by a significant increase of type I and II collagen mRNA expression. 
Instead it was followed by a decrease of type III collagen mRNA expression particularly 
evident at twelve moths of ages (Figure 18 B).  
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Figure 18: Total tissue collagen measured as hydroxyproline and quantitative RT-PCR of type I and 
III collagens. (A) Values are expressed as the percent changes (mean±S.D.) from the mean values obtained 
in 2 month-old C57Bl/6J WT and Tsk mice, respectively. Tissue hydroxyproline values in 2month-old WT 
and Tsk mice were 273.2±20.4 and 265.8±17.2 µg/penis, respectively. Data were from 6 penises of each 
strain of mouse at the different ages. **p < 0.01 vs their respective 2 month old reference mice. 
(B) A significant increase in expression of types I and III collagens appear evident at 6months of age. This is 
followed by decreased expression of type III collagen from 10 months of age onwards. *p < 0.01 vs their 
respective 2 month-old reference mice. 
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2.3.4  Biochemical analysis for TGFβ 
The results obtained by immunostaining for TGFβ showed a soft positive reaction 
around the small vessels in the tunica albuginea of Tsk mice at two months of age (Figure 
19 A). More marked positive staining was observed at six and eight months (Figure 19 B 
and Figure 19 C, respectively). Instead the immunostaining for TGFβ was less intense in 
penile tissues of Tsk mice at twelve months of age (Figure 19 D). 
The positive immunostaining for TGFβ, instead, was totally absent in the penis of 
C57B1/6J wild type animals at various age. 
In addiction quantitative RT-PCR was performed for TGFβ; the results are reported in 
Figure 19 E. 
According to the immunohistochemical results the maximal increase of TGFβ was 
observed at six and eight months of age.  
The level of TGFβ slowly declined thereafter reaching a significant difference at 
twelve months with respect to those observed at eight months.  
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Figure 19: (A–D) Representative immunohistochemical reaction for TGFβ in the tunica albuginea 
(TA) of Tsk mice at various ages. TA of Tsk mice at 2 (A), 6 (B), 8 (C) and 12 (D) months of age. TGFβ 
staining is mainly detected around the small vessels (arrow). TGFβ expression is evident from 2 months of 
age (A) onwards. Maximum staining is observed at 6 (B) and 8 (C) months of age. A less intense staining of 
TGFβ is still present at 12 months of age (D). Counterstained with haematoxylin, original magnification 
×200. (E) Quantitative TGFβ expression. TGFβ expression in Tsk penises at different ages is reported. The 
TGFβ signal is significantly increased at 6 and 8 months of age compared to 2 month-old Tsk mice. A 
significant decrease in TGFβ expression appears evident from 12 months. *p < 0.01 vs their respective 2 
month-old reference mice. 
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2.3.5 RT-PCR analysis for iNOS 
The results of RT-PCR analysis of iNOS expression are reported as mRNA for six,   
eight, ten and twelve months old for Tsk mice (Figure 20). The values are calculated 
relatively to that obtained from two months old mice.  
 RT-PCR revealed an increase of iNOS expression with disease progression in Tsk 
mice. 
 
 
 
 
 
 
  
Figure 20: Quantitative RT-PCR of iNOS. 
iNOS mRNA expression progressively increases with age. 
*p < 0.01 vs their respective 2month-old reference mice.  
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2.4  Discussion 
Peyronie's disease is an acquired inflammatory condition of the penis characterized by 
the development of plaque in the tunica albuginea. This pathological condition is 
associated with penile curvature, erectile dysfunction and, in some cases, pain. Smith et al., 
sowed that  the prevalence of PD  affect 3.2 %  of the male population, (Smith et al., 2005; 
Schwarzer et al,. 2001). About two-thirds of these are between 45 and 60 years old, 
although an age range of 18 to 80 years has been reported.   
Over 250 years after the first description by Francois de la Peyronie, as the exact 
causes of PD remain enigmatic, it is not surprising that many treatment option have been 
tried for this condition (Ralph et al,. 1992). Many of the theories seek to explain the 
pathogenesis of PD: while trauma is considered to be the provocative stimulus, other 
theories include failure of fibrin clearance, collagen alterations, genetic predisposition, 
autoimmune factors, free radical production, and cytogenetic aberrations (Smith et al., 
2005). Many of these theories are based on an animal (in vivo) and cell culture (in vitro) 
models. The in vivo models are attained by the injection of both TGFβ (El sakka et al., 
1997; El Sakka et al., 1998) or fibrin (Davila et al., 2003) into the rat tunica albuginea. The 
cell culture model was explained by Mulhall et al. whose derived cultured cells from 
plaque tissue; this in vitro analysis showed reliable phenotypic, genotypic and functional 
alterations in pathological tissue compared to normal tunica-derived or neonatal foreskin 
derived fibroblasts (Mulhall  et al., 2002). Nevertheless these model was not able to 
flawlessly replicate the in vivo environment. These studies suggests the major role of TGFβ 
signalling pathway in the development of disease but it is easy understood that actually the 
difficulty in PD diagnosis  and therapies is the lack of an appropriate experimental model.  
With the study reported here we described a spontaneous model of PD in the Tsk mice 
that with age could reproduce the natural development of human PD. This represents the 
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first spontaneous animal model. The Tsk mutation, consisting with a tandem duplication of 
the fibrillin I (FbnI) gene resulting in a larger transcript, discovered in 1976 (Christner and 
Jimenez 2004). As the FbnI gene participates at the microfibril formation, the Tsk mouse 
has been proposed as a model of scleroderma and fibrosis (Jimenenz SA et al., 1984; 
Green et al., 1976).  
Male Tsk mice were monitored for twelve months to evaluate the homologies and the 
differences with the human disease.  As in the human pathology, in the Tsk mice the 
disease develops slowly with age and progresses until twelve months when the gross and 
microscopic appearance of penis are similar to those reported in PD patients. No further 
progression was observed from twelve months of age onwards. In the first stage of the 
disease, during six months of age, there was the presence of inflammatory infiltrates 
beneath the tunica albuginea, disorganization of the outer layer and thickening of the inner 
layer due to increased collagen deposition. From eight months on there is an increase of 
disorganization and accumulation of collagen until twelve months, the later stage, 
characterized by the presence of thickened plaques of fibrous tissue in the tunica albuginea. 
Like in the human disease the formation of fibrotic plaques alters penile anatomy causing 
different pathological degrees (Bevilacqua et al., 2000).  The development of PD in Tsk 
mice is characterized by a gradual increase in synthesis and deposition of collagen. In 
particular we have observed a relative increase of collagen of type I, that may greatly 
contribute to the penile stiffness, to the detriment of the more elastant type II collagen. The 
collagen  accumulation in the penis of Tsk mice may be driven also in cooperation with 
other cytokines. In fact RT-PCR revealed high level of TGFβ especially in the earlier stage 
of the disease. Probably various pathways, which involve different cell type, growth and 
vasoactive factor, are implied in the collagen deposition and consequent fibrosis process. 
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At this regard we have demonstrated that iNOS could be involved in PD ; in fact RT-PCR 
for iNOS revealed an increase of mRNA level during the development of the pathology.  
In conclusion, the Tsk mouse, as it replicates similar condition to the human disease, 
may represents a new animal model of PD naturally occurring, thus by using this 
especially model it is could be possible to develop in features some therapeutical 
approaches for PD disease. 
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3.1 Urotensin II 
Urotensin II (UII) is a disulphide-bridged peptide that was originally isolated from the 
goby Gillichthys Mirabilis urophysis (Bern et al., 1979) (Figure 20 a).  
UII isoforms were identified in many species of fish (Bern et al.; Colon et al., 1996), as 
well as in amphibians (Conlon et al., 1992) and mammals, including man (Coulouarn et 
al., 1999). It has been shown that UII acts by a specific receptor, belonging to the 
superfamily of G-protein-coupled receptors (GPCRs). This receptor was previously known 
as an orphan G-protein coupled receptor (GPR14) and now designed as UT receptor 
(Figure 19 b) (Foord et al., 2005). UII amino-terminus region diverges between species 
while all isoforms share a conserve, cyclic hexapeptide, core-sequence motif of CFWKYC. 
The fact that U-II isopeptide is conserved over a wide range of evolutionary levels, 
indicates that the cyclic region retains full biological activity as a UT receptor ligand.  
 
 
Figure20: Representation of UII and UT receptor. 
(a) Structure of human (h-)UII: peptide contains a disulphide bridge between the two cysteine residues that 
cyclises the peptide into its biologically active conformation. The cyclic hexapeptide core, the conservative 
portion, is receded by an acid residue and followed by a neutral residue in h-UII. (b) Schematic structure of 
UT receptor: UII-binding determinants are located in the extracellular loops and the top portion of the 
transmembrane domains.    
 a b 
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UII and UT receptor are expressed in variety of peripheral organs (liver, kidney, 
endocrine glands) and especially in cardiovascular tissues (cardiomyocyte, endothelium, 
and vascular smooth muscle cells) (Conlon et al., 1996; Ames et al., 1999).   
Several studies have revealed that UII produces potent but variable constrictor effects 
in some but not in all vascular beds. Indeed, UII was described as the most potent 
vasoconstrictor identified by now (Ames et al., 1999); in fact Douglas et al. showed that 
UII is more potent than endothelin-1 (Douglas et al., 2000). On the other hand, it has been 
also demonstrated  a vasodepressor and regionally selective vasodilator effect of UII 
(Bottril et al., 2000; Gardiner et al., 2001). The role of UII in cardiovascular system seems 
to be both species and vascular bed-dependent (Douglas 2000; Camarda 2002).  In fact in 
vitro studies performed by Gibson et al. in 1987, showed that on intact rat aortic strips 
precontracted by noradrenaline low concentration (0.1-0.5 nM) of UII induced 
vasodilation, while higher concentrations (1-10nM) caused further contractions. After 
removal of the endothelium the vasodilation was absent but the contractile response 
remained (Gibson, 1987). The contractile effect of UII was also observed in isolated rat 
carotid arteries and left anterior descending coronary arteries, whereas no effect was 
observed in isolated small mesenteric arteries (Bottril et al., 2000). When these vessels 
were first precontracted with metoxamine, UII caused endothelium-dependent relaxation 
(Bottril et al., 2000). In non human primates, UII caused vasoconstriction in large vessels 
such as aorta (Ames et al., 1999), coronary arteries (Ames et al., 1999) and pulmonary 
arteries (Zhu et al., 2004). In addition, even in man arteries isolated from heart (Maguire et 
al., 2000; 2004) and lung (MacLean et al., 2000; Stirrat et al., 2001; Bennet et al., 2004) 
was observed a vasoconstrictor effect of UII. Instead in human small resistance vessels 
such as abdominal resistance arteries Stirrat et al. (2002) observed an UI-induced 
relaxation, while in human skin microvasculature, there was no response to UII  (Hillier et 
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al., 2001).   Besides, as the presence of the peptide in pmolar concentrations in blood in 
healthy individuals, the U-II/UT receptor system seems to play an important role in 
cardiovascular function (Cheung 2004; Douglas 2004). Several studies reported that 
cardiovascular effect of UII include positive inotropy in human and rat myocardium 
(Russel et al., 2001; Russel and Molenar 2004; Gong et al., 2004), although negative 
ionotropy has been showed in canine cardiomyocites and in rabbit papillar muscle (Fontes-
Sousa et al., 2007). On the other hand, in vivo studies showed that, in anesthetized 
monkey, systemic administration of U-II caused circulatory collapse as result of the 
profound vasoconstrictor effect of the peptide (Ames 1999). Conversely, infusion of U-II 
did not cause any significant change in heart rate, mean arterial pressure or cardiac index in 
healthy male volunteers (Affolter et al., 2002). In anesthetized rats intravenous injection of 
U-II showed an hypotensive effect partially mediated by NO (Abdelrahman  and Pang 
2002). 
Two vascular effect of UII are regulated by the balance of the UII/UT receptor system on 
the vascular smooth muscle and on the endothelium. It has been demonstrated that 
inhibition of phospholipase C (PLC) inhibited the contractile response induced by UII 
(Saetrum et al., 2000). On these basis it has been showed that the contractile effect is 
mediated by an increase of phosphoinositide (PI) turnover, with a subsequent increase in 
intracellular Ca++ (Ames et al., 1999; Filipeanu et al., 2002). Influx of intracellular calcium 
through the activation of L-type calcium channel, is also responsible for the UII induced 
increase in intracellular calcium and hence vasoconstrictor actions (Maguire and 
Davenport 2002) (Figure 22). Instead vasodilatatory response to UII appear to be 
dependent on the presence of endothelium. The endothelium-dependent vasorelaxation 
observed on precontracted rat coronary arteries, was abolished in the presence of the eNOS 
inhibitor L-NAME (Bottril et al., 2000). It has been showed that vasodilation is caused by 
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UII-mediated increases in intracellular calcium in endothelial cells, resulting in release of 
the endothelial-derived relaxing factors: both NO and endothelium-derived hyperpolarizing 
factor (EDHF) (McDonald et al., 2007) (figure 22). In addition to endothelial factors, 
variations in both the vasodilatatory and constrictor response to UII might reflect the 
expression of the UT receptor which, in part, will  depend on the size and location of the 
vessel (Onan et al., 2004).  
It is well known that corpus cavernosum is an highly vascularised tissue whose 
function is dependent upon a balance between the vasodilatory and the vasoconstrictory 
tone. In penile erection there is a strong involvement of the vascular system and the L-
arginine/NO pathway plays a major role (Ignarro 1990).  
Thus we aimed to address part of our study in this issue, in particular we investigated: 
i) the involvement of UII/UT receptor pathway  in the penile erection and ii) molecular 
mechanisms induced UII vascular effect.  
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Figure 22: UT receptor signalling. 
UT receptor is coupled with  Gαq/11 subtype of heterometrimeric G proteins. Activation of Gαq/11 on smooth 
muscle cell leads an increase in inositol triphosphate and mobilization of intracellular Ca2+ with following 
contraction. On endothelium the activation of UT receptor may cause a release of EDHF and eNOS 
activation following in vasodilation.   
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3.2  Materials and methods 
 
3.2.1 Investigation of UII/UT receptor pathway  involvement in the penile 
erection 
 
3.2.1.1 Peptide synthesis 
The human U-II was synthesized and purified at the Department of Pharmaceutical and 
Toxicological Chemistry of the University of Naples, Federico II. The peptide was 
obtained by solid-phase peptide synthesis (Grieco et al., 2000;45:4391–4). Purification was 
achieved using a semi-preparative reversed phase high-performance liquid chromatography 
(HPLC) C18 bonded silica column. The purified peptide was 99% pure as determined by 
analytical reversed-phase HPLC. The correct molecular weight was confirmed by mass 
spectrometry and amino acid analysis.  
 
3.2.1.2 Human Corpus Cavernosum  
The human corporus cavernosum (HCC) was excised from the penis with male-to-
female transsexual surgical procedures. All patients were informed of all procedures and 
gave their written consent. The protocol was approved by the Ethics Committee of the 
Medical School of the University of Naples Federico II. Patients undergo appropriate 
hormonal pre-treatment with antiandrogens and estrogens to adapt to female appearance, 
and the therapy is discontinued 2 months before surgery. After amputation tissue was 
immediately placed in ice-cold oxygenated Krebs’ solution (Mirone et al., 2000). Krebs’ 
solution had the following composition (mM): 115.3 NaCl; 4.9 KCl; 1.46 CaCl2; 1.2 
MgSO4; 1.2 KH2PO4; 25.0 NaHCO3; 11.1 glucose. 
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3.2.1.3 Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR) for UII receptor (GPR14) 
The presence of GPR14 was determined by quantitative PCR. After  isolation mRNA 
from HCC and human colon tissue and subsequent preparation of cDNA, reverse 
transcription was performed and 100 ng of the RNA samples described earlier were used 
for quantitative PCR. Samples were run in triplicate in 50 µL reactions by using an ABI 
PRISM 7500 sequence detector system. Amplification was done using Hs01027998_s1 
Taq Man Gene Expression assay amplification set up and cycling were performed 
according to manufacturer’s recommendations. 
 
3.2.1.4 Western blot analysis for UII receptor (GPR14) 
Human or rat corpus cavernosum were homogenized in modified RIPA buffer (Tris-
HCl 50 mM, pH 7.4, Triton 1%, sodium deoxycholate 0.25%, NaCl 150 mM, 
ethylenediaminetetraacetic acid 1 mM, phenylmethylsulphonyl fluoride 1 mM, aprotinin 
10 mg/mL, leupeptin 20 mM, NaF 1 mM, sodium orthovanadate 1 mM) by liquid nitrogen. 
Protein concentrations of cell lysates were estimated by the Bio-Rad protein assay using 
BSA as standard. Equal amounts of protein (40 µg) of the cell lysates were dissolved in 
Laemmli’s sample buffer, boiled for 5 min, and subjected to SDS-polyacrylamide gel 
electrophoresis (10% polyacrylamide). Western blotting was performed by transferring 
proteins from gel to a sheet of polyvinylidene fluoride membrane at 250 mA for 60 min at 
room temperature. The filters were then blocked with phosphate-buffered saline (PBS) 
containing 5% nonfat dry milk (PM) for 45 min at room temperature and incubated with 
rabbit polyclonal antibody for GPR14 (H-90) (1:1000) in 1x PBS, 5% nonfat dried milk 
and 0.1% Tween 20 (PMT) overnight at 4°C. Than the membranes were extensively 
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washed in PBS containing 0.1% v/v Tween 20, before incubation for 2 hours with 
horseradish peroxidase-conjugate anti mouse secondary antibody (1:5,000). Membranes 
were then washed and developed using enhanced chemiluminescence substrate. . To 
ascertain that blots were loaded with equal amounts of protein lysates, they were also 
incubated in the presence of the mouse β-actin antibody. The protein bands were 
densitometrically analysed with a model GS-800 imaging densitometer. 
 
3.2.1.5 Immunofluorescence on HCC 
HCC samples were fixed in 4% formalin buffer and paraffin-embedded. Cross-sections 
were cut (6 mm) and used for the detection of specific proteins by immunofluorescence. 
Paraffin sections, after being de-waxed and rehydrated, were boiled for 30 minutes in 
citrate buffer for antigen retrieval. The sections were incubated in blocking buffer (PBS 
with 1% casein) for 1 hour at room temperature in a humidified chamber. Endogenous 
biotin was blocked with the Avidin/Biotin Blocking Kit. The sections were incubated 
(4°C) overnight with anti-GPR14 goat polyclonal antibody (1:100) diluted in 1% blocking 
reagent 0.3% Triton X-100 in PBS. Sections incubated with 1% goat serum were used as 
negative controls. Subsequently, sections were incubated with donkey anti-goat secondary 
antibody Texas Red conjugated (1:100) for 30 minutes. After washing, sections were 
incubated for 1 hour with mouse monoclonal anti-a-smooth muscle actin (a-SMA) 
antibody fluorescein isothiocyanate (FITC) conjugated (1:250), or for 2 hours with rabbit 
polyclonal anti-von Willebrand factor (vWF; 1:100) and donkey anti-rabbit secondary 
antibody FITC conjugated (1:100) for 30 minutes. 4′,6-Diamidino-2-phenylindole was 
used to stain the nuclei. Images were taken with the aid of a Leica DFC340 FX video-
camera connected to a Leica DMRB microscope using Leica Application Suite software 
V2.4.0 and processed with Adobe Photoshop 7.0 software. 
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3.2.1.6 Human corpus cavernosum preparation and functional studies   
HCC was dissected in longitudinal strips (2cm) and used for functional studies in 
isolated organ bath filled with oxygenated (95%  O2 and 5% CO2) Krebs’ solution at 37°C. 
Strips were stretched until a resting tension of 2g and allowed equilibrated for at least 90 
minutes during which tension was adjusted, when necessary, to 2g and bathing solution 
was periodically changed. After equilibration, tissues were standardized by performing 
repeated phenylephrine (PE; 1 mM; Sigma) contractions until three equal responses were 
obtained. In orther, to verify endothelium integrity, acetylcoline (Ach) cumulative 
concentration-response curve (0.01–10 mM ) was performed on PE precontracted strips. 
Strips without a functional endothelium (non responsive to Ach) were obtained by 
incubating in distilled water for 15 seconds. In the first set of experiments a concentration-
response curve to U-II (0.1 nM to 10 mM) was obtained using HCC strips under resting 
condition. In the second step UII cumulative concentration-response curve (0.1 nM - 10 
µM) was obtained in the presence or absence of endothelium, using HCC strips pre-
contracted with PE (1 mM). To assess the involvement of NO, we incubated the strips for 
30 minutes with N (G)-nitro-L-arginine methyl ester (L-NAME; 100 mM), NOS inhibitors, 
before U-II challenge. Data were calculated as % of relaxation to PE tone and expressed as 
SEM from eight separate specimens from four different tissues. The results were analyzed 
by using analysis of variance (ANOVA) followed by Bonferroni post hoc test. 
 
3.2.1.7 Measurement of nitrite and nitrate (NOx) in HCC strips  
HCC strips were incubated with UII (0.1 µM) or vehicle (water) for 30 minutes at 
37°C. The reaction was stopped in liquid nitrogen. Homogenate of HCC strips and a 
standard curve of sodium nitrate were incubated in a microplate with cadmium 
(50 mg/well) for 1 h to convert NO3− to NO2− (Thomsen et al., 1990). After centrifugation 
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at 14,000 rpm for 15 min, total nitrite (NOx) content was determined fluorometrically in 
microtiter plates using a standard curve of sodium nitrite (Misko et al., 1993 Anal. 
Biochem. 214 pp. 11–16). NOx content was calculated by using the internal standard 
curve. 
 
3.2.1.8 Intracavernous Administration of UII in Anesthetized Rats in vivo 
The present study was performed in accordance with the guidelines of Italian law 
(N.16/1992) and European Council law (N.86/609/CEE) for animal care. The experimental 
procedures were approved by the Animal Ethics Committee of the University of Naples. 
Male Wistar rats (200–250 g) were obtained from Harlan and kept under laboratory 
conditions (temperature 23±2°C, humidity range 40–70%, 12-hour light/dark cycle and 
food and water ad libitum). In anesthetized rats (with an intraperitoneal injection of 
urethane- 1 g/kg), an heparinized (5 I.U./mL) polyethylene catheter was introduced into the 
carotid artery and connected to a pressure transducer (BLPR-2) to measure systemic blood 
pressure. After a midline perineal incision, followed by blunt dissection of the overlying 
striated muscles, a 26G-gauge needle attached to an heparinized (10 I.U./mL) polyethylene 
catheter was inserted into the corpus cavernosum and the intracavernous pressure (ICP) 
was monitored with a pressure transducer (BLPR-2),. These parameters were recorded and 
data acquisition and calculations were performed using a computer system (Biopac), 
(Figure 23). 
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Figure 23: (A) Incanulation of rat intracavernous root to evaluate the intracavernous pressure. (B) 
representative tracing of an intracavernous pressure increase after UII intracavernous administration. 
 
 
 For pharmacological evaluation via the intracavernous roote, a 26G-gauge needle was 
placed at the other crus for drug injection. U-II was given at doses of 0.1, 0.3, 1.0 nmol/rat 
dissolved in 50 µL saline. To validate the experimental model we used Ach (2.5, 5.0, 25.0 
nmol/rat). Saline served as the control vehicle (50 µL). Data were calculated as delta (mm 
Hg) of ICP and as area under the curve (mm Hg x min) and expressed as mean±SEM from 
five separate experiments. The changes in systemic blood pressure were calculated as 
differences from basal values following intra-cavernous drug injection (delta mm Hg) and 
expressed as mean±SEM. Data were analyzed using ANOVA followed by Bonferroni. 
 
 
3.2.2 Relationship between UII/UT receptor pathway and L-arginine/NO 
pathway 
We have investigate on the mechanism of eNOS activation to evaluate how UII/UT 
receptor pathway promotes NO production. 
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3.2.2.1 Western blot analysis 
Preliminary time course study was performed incubating HCC strips for 5, 15, 30 or 60 
minutes with either UII (10 µM) or vehicle (water). The experimental time selected was 30 
minutes. At this time HCC strips were incubated with water, UII, geldanamicin (Hsp90 
inhibitor) (1 µM), wortmannin (Akt inhibitor) (1 µM and 100 mM) and with DMSO 
(wortmannin and geldanamicin  vehicle). The reaction was stopped by liquid nitrogen. 
Tissues are homogenised as previously described.  
Western blot analysis was performed using 50 µg of denaturated proteins, separated on 
8% sodium dodecyl sulphate polyacrylamide gels and transferred to a PDF membranes. 
After 45 minutes of blocking in PM containing NaF (50 mM), membranes were incubated 
overnight at 4°C with rabbit polyclonal anti p-eNOS antibody (1:1000). The filters were 
extensively washed in PMT before incubation for two hours with anti-rabbit antibody. 
Membranes were then washed and developed using ECL. The same membranes were 
incubated overnight at 4°C with mouse monoclonal eNOS antibody. Filters were exposed 
to ECL after 2 hours of incubation with horseradish peroxidise-conjugate antimouse 
antibody. To ascertain that blots were loaded with equal amounts of protein lysates, they 
were also incubated in the presence of the mouse β-actin antibody. The protein bands were 
densitometrically analysed with a model GS-800 imaging densitometer. 
 
 
3.2.2.2  Functional studies  
HCC strips were equilibrated in isolated organ bath as previously described. After 
standardization, on a resting condition, tissues were incubated with Hsp90 inhibitor 
(geldanamicin, 1 µM), or with Akt inhibitor (wortmannin 1 and 0.1 µM) or with vehicle 
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(DMSO).  After 30’ of incubation UII cumulative concentration-response curve (0.1 nM - 
10 µM) was performed on HCC strips pre-contracted with PE (1 mM).  
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3.3 Results  
 
3.3.1 UII/UT receptor pathway is involved in penile erection in rats 
Western blot analysis performed on rat corpusu cavernosum showed that UT receptor 
is expressed in rat penile tissue (Figure 24).  
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Representative western blot for urotensin II receptor (GPR14) in  
rat corpus cavernosum. β-actin was used as loading control. 
 
 
 
 
 
 
In order to evaluate if UII could cause penile erection in vivo, we have practised an 
intracavernous administration of peptide. During these experiments we have monitored 
both systemic and intracavernous pressure. Administration of U-II (0.1; 0.3; 1.0 nmol/rat) 
induced a dose-dependent increase in ICP (Figure 25 A and B), thus penile erection, 
without modify significantly the mean arterial blood pressure (Figure 25 D). The data are 
expressed as delta of increase in ICP (Figure 25 A, ***P < 0.001) as well as area under the 
curve (Figure 25 B, ***P < 0.001). To validate the experimental procedure we used Ach 
(2.5, 5.0, 25.0 nmol/rat), which caused a dose dependent increase in ICP (Figure 25 C; 
*P<0.05,  **P<0.01) and a reduction of blood pressure in a dose-dependent manner (data 
not shown).  
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Figure 25: Effect of urotensin II (U-II) on intracavernous and systemic pressure in anesthetized rats. 
U-II (0.1, 0.1, 1 nmol/rat) caused significant dose-dependent increases in intracavernous pressure (ICP) 
compared with saline. The data are expressed in (A), as delta in mm Hg (***P < 0.001; N = 5) and in (B), as 
area under the curve (***P < 0.001; N = 5). (C) Ach (2.5, 5, 25 nmol/rat) caused a dose-dependent increase 
in intracavernous pressure (*P < 0.05, **P < 0.01, N = 5). (D) U-II did not cause any change in arterial blood 
pressure. Data expressed as mean±SEM were analyzed by one-way ANOVA. 
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3.3.2 HCC distribution of UII receptor 
 UT receptor is expressed in human corpus cavernusum either as protein or as mRNA; 
and  are reported in Figure 26 A and B respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 26: (A) Representative western blot for GPR14 in human corpus cavernosum. β-actin was used as 
loading control. (B) Quantitative reverse transcriptase polymerase chain reaction for GPR14 in human corpus 
cavernosum; as control we used human colon tissue. The data represent the mean ±standard error of the mean 
of three different human and rat specimens. 
 
A B 
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In addition, the immunofluorescence analysis, performed to locate UT receptor expression, 
demonstrated a robust signal for GPR14 on HCC (Figure 27-2B, C). Negative control 
slides showed no signal (Figure 27 A). The co-localization of UT receptor with  
endothelial cell marker, vWF, clearly showed a strictly overlapping of the signals 
indicating that UT receptor was expressed by endothelial cells of the vessels (Figure 27 B). 
Instead, a positive signal for UT receptor was not showed on smooth muscle cells, marked 
by α-SMA (Figure 27 C). A signal for GPR14, even if less evident, was also visible in the 
endothelium of sinusoids (data not shown). 
 
 
Figure 27: Localization of UT receptor (GPR14) in human corpus cavernosum. 
Photomicrographs show cellular localization of the GPR14 protein (red) with immunofluorescence. Panel A: 
negative control. Panel B and C: Sections were doubled stained with an endothelial cell marker (von 
Willebrand factor [vWF]; green) (B), or with a smooth muscle cell marker (a-SMA; green) (A, C). 4i,6-
Diamidino-2-phenylindole (blue) was used to stain the nuclei. The merges showed the GPR14 co-localization 
(yellow). Results illustrated are from a single experiment and are representative of three different specimens. 
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3.3.3 Effect of UII on HCC strips 
U-II (0.1 nM–10 mM) administration on HCC strips, under resting condition, did not cause 
vasoconstrictor effect (Figure 28 A). Instead the peptide induced relaxation in endothelium 
and  concentration-dependent manner when HCC strips were precontracted with PE 1 µM 
(Figure 28 B; ***P < 0.001). In fact the absence of endothelium abrogated the response to 
UII (Figure 28 B). 
 
 
Figure 28: Urotensin II (U-II) effect on human corpus cavernosum (HCC) strips. 
 (A) UII did not contract HCC strips in restin condition. (B) U-II relaxed HCC strips precontracted with PE 
(3 mM) in presence of endothelium (***P < 0.001). Data expressed as mean±standard error of the mean were 
analyzed by analysis of variance and by Bonferroni as post-test. 
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 3.3.4 Involvement of L-arginine/NO pathway in UII-induced relaxation 
In order to evaluate a possible involvement of NO/eNOS pathway, we have tested the 
effect of L-NAME, an eNOS inhibitor, on UII-induced vasorelaxation. The incubation with 
L-NAME, at the concentration of 100 µM for 30 minutes under resting condition, 
abrogated the effect of vasorelaxation induced by UII on precontracted HCC strips (Figure 
29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Eeffect of L-NAME on UII-induced relaxation. 
eNOS inhibitor (100 µM, 30 minutes) abolished the vasodilatant response induce by UII 
on HCC strips precontracted with PE (1 µM). Data expressed as mean±standard error of 
the mean (N = 8) were analyzed by analysis of variance and by Bonferroni as post-test. 
CTR = control. 
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3.3.5 UII increase NOx production in HCC strips  
In order to evaluate the involvement of eNOS, we have assessed if there was a modulation 
of eNOS post-translational activation. To address this specific issue we have monitored 
NOx production. In basal conditions HCC strips produce an amount of NO, measurable as 
total nitrite. When HCC strips were stimulated with UII (10 µM for 30 minutes), NO 
production significantly increases (Figure 30; *p<0.05). Thus, pre-treatment with UII 
could modulates eNOS activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Effect of UII on NOx production in HCC strips. 
Total nitrite (NOx) content was determined fluorometrically using a standard 
curve of sodium nitrite. Data are expressed as mean±S.E.M, n=3, *p<0.05. 
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3.3.6  UII phosphorylates eNOS  
Preliminary western blot analysis performed on HCC strips incubated with vehicle or 
with UII (10 µM) for 5, 15, 30 and 60 minutes showed that peptide induced 
phosphorylation of eNOS in time-dependent manner. The densitometric analysis is 
expressed as p-eNOS/eNOS ratio. The incubation with UII caused a time-dependent  
increase of p-eNOS/eNOS ratio. This effect was significant when UII was incubated for 30 
minutes compared with vehicle (CTR) (Figure31).  
 
 
 
Figure31: eNOS and phosphorylated (p)-eNOS evaluation in HCC strips. 
Representative western blot for eNOS and phosphorylated eNOS (p-eNOS) in HCC strips stimulated with 
UII (0.1 µM) at different time, or with vehicle (ctr). Densitometric analysis shows a significant (* p < 0.05) 
change in the eNOS–p-eNOS ratio following 30 minutes of treatment with UII vs ctr. 
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From these results 30 minutes was selected as time of incubation to evaluate the effect 
of  Akt and Hsp90 inhibitors on p-eNOS phosphorylation induced by UII. 
At first western blot analysis showed that DMSO, the vehicle of wortmannin and 
geldanamicin, did not alter the basal level of the ratio p-eNOS/eNOS  (figure 32). The 
incubation with wortmannin, at various concentration (1 and 0.1 µM), for 30 minutes 
reverted the eNOS phosphorylation induced by UII (Figure 32, °p<0.01 vs UII). Instead, 
pre-treatment with geldanamicin (1 µM), did not alter the UII induced eNOS 
phosphorylation (**p<0.001 vs ctr and DMSO).   
 
 
Figure 32:  Evaluation of p-eNOS phosphorylation. 
Representative western blot for eNOS and phosphorylated eNOS (p-eNOS) in HCC strips incubated with 
wortmannin (1 and 0.1 µM), geldanamicin (1 µ), or DMSO before the treatment with UII (10 µM).  
Densitometric analysis showes that wartmannin, at both doses, but not geldanamicin, inhibits UII induced 
phosphorylation in HCC strps (°p< 0.01).   .
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3.3.7  UII activates eNOS via Akt and Hsp90 
 
Functional studies in vitro showed that pre-treatment with both wortmannin (1 and 0.1 
µM) and geldanamicin (1 µM), Akt and Hsp90 inhibitors respectively, inhibited the 
relaxation induced by UII on HCC strips (Figure 33). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Effect of Akt and Hsp90 inhibitors on  UII-induced relaxation. 
  Pre-tratment with either, wortmannin (1 and 0.1 µM) and geldanamicin (1 µM) for 30 minutes, inhibited the 
vasodilatant response induce by UII on HCC strips precontracted with PE (1 µM). Data expressed as 
mean±standard error of the mean were analyzed by analysis of variance and by Bonferroni as post-test.  
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3.4 Discussion 
UII is a vasoactive ‘somatostatine-like’ cyclic peptide that was originally isolated from fish 
spinal cors (Bern et al.,  1985; Conlon et al., 1996), and that has recently been cloned from 
human (Coulouarn et al., 1999). The UII sequence appears well conserved in the evolution 
of vertebrates (Conlon et al., 1997). This might suggest important physiological roles for 
this peptide. In fact the peptide and its receptor are abundantly distributed in human heart , 
brain, pancreas, skeletal muscle, vascular smooth muscle and endothelial cells, spinal cord, 
and endocrine tissue (Ames 1999; Maguire 2000). The vasoactive effects of U-II seem to 
be dependent upon the caliber of the vessels and the species (Camarda et al., 2002; 
Douglas et al., 2000; MacLean et al., 2000). For instance, in the rat, UII contracts many 
arteries such as thoracic aorta, carotid, pulmonary and coronary arteries (Douglas et al., 
2000; MacLean et al., 2000). Its vasoconstrictor effect on the rat thoracic aorta is mediated 
by phospholipase C and protein kinase C-dependent pathway (Rossowsky et al., 2002). 
Conversely, it has been suggested that U-II-effect in resistance vessels in rat and human, 
causes vasodilation involving NO pathway (Bottrill et al., 2000.;Stirrat et al., 2001; Zhang 
et al., 2003). Thus, the cardiovascular actions of this peptide can be influenced by regional 
factors such as receptor distribution and the species considered. To date it is unclear 
whether the predominant action of U-II in human disease will be deleterious or protective. 
At these regards, also  in vivo studies are controversial. In fact in conscious rats UII at high 
doses (3000 pmol.kg-1) causes an overall depressor effect, causing dilatation of vascular 
beds, resulting in reduced men arterial blood pressure and tachycardia (Gardiner et al., 
2001). Instead in cynomolgus monkeys the intra venous administration of the peptide at 
low doses result in an increase in cardiac output and regional vasodilation, while high 
doses lead to a fatal combination of increased vascular resistance and only moderate 
reduction in blood pressure, coupled with a decrease in cardiac output (Ames et al., 1999). 
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In addition, recently, it has been demonstrated that the endothelium may be determinant for 
changes in vasomotor tone to U-II in vivo. In fact an alteration of U-II/UT receptor 
pathway contributes to the development of several cardiovascular disorders associated to 
endothelial dysfunction. Indeed, elevated plasma levels of U-II have been detected in 
patients with various cardiovascular disease states including heart failure, hypertension, 
renal dysfunction, and diabetes (Gruson et al., 2006; Suguro et al., 2007; Totsune et al., 
2004; Totsune et al., 2003). On the other hand it has been showed that intracelebral 
injection of UII causes hypertension, bradycardia, increase in locomotor activity without 
alter the penile function (Do-rego et al., 2005). In penile erection there is a strong 
involvement of the vascular system and the L-arginine/NO pathway plays a major role 
(Ignarro et al., 1990). To evaluate the possible link between UII and NO in penile tissue, 
we have investigated if UII could act as an endogenous mediator in HCC and thus be 
involved in penile erection. First we address the question if the penile tissue express the 
receptor. Our data showed that GPR14 is expressed in rat corpus cavernosum. Thus, by in 
vivo experimental model, we have monitored the intracavernous pressure after UII local 
administration. The results demonstrated that intracavernous administration of peptide in 
anesthetized rats induced a dose- dependent increase in ICP implying that UII is involved 
in rat penile erection. In addition  UII did not cause any significant change in systemic 
blood pressure, at all doses tested. Next we address the question if the human tissue 
expresses the receptor and where it is localized. HCC was obtained from patients 
undergoing sex change. The human tissue possesses the UT receptor as protein as well as 
mRNA. Particularly, the immunofluorescence highlighted a strongly stained for UT 
receptor exclusively on the endothelial cells of the HCC tissue, implying that UII might 
play a role in the HCC vasodilatory response. These data are confirmed by other results 
obtained by using in vitro functional studies. In fact we have proved that UII did not have a 
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vasoconstrictor effect on HCC strips in resting condition. Conversely, on HCC strips 
precontracted by PE, the peptide induced relaxation in a concentration- and endothelium-
dependent manner. Thus we have evaluated the possible link between UII vasorelaxant 
effect and L-arginine/NO pathway. To analyze this possibility we assessed the effect of UII 
after pre-treatment with L-NAME. The inhibition of eNOS abrogated U-II-induced 
relaxation with a profile overlapping the inhibition operated by the removal of endothelium 
supporting our working hypothesis. These data are consistent with the analysis of NOx 
production in HCC strips. In fact, in HCC strips stimulated with UII, NO production was 
significantly increased up than basal condition, implying the involvement of NO pathway 
in UII effect. Our results are consistent with several evidence indicating that stimulation of 
UT receptors on animal vascular endothelial cells can trigger the release of NO (Bottrill et 
al.,  2000; Zhang et al., 2003; Katano et al.,  2000; Ishihata et al., 2005; Gardiner et al., 
2006). In addition, U-II binding sites have been localized to vascular endothelial cells, 
confirming that U-II stimulates NO-dependent vascular relaxation (Douglas et al., 2000). 
In the last step of this study we have investigated on the molecular mechanism of UII 
eNOS activation. In the last several years, many protein partners that interact with eNOS 
have been described, including caveolin-1, calmodilin (CaM), heat shock protein 90 
(Hsp90) and certain kinases including Akt (Bernier et al., 2000; Michell et al., 1999). The 
caveolin-1 binding to eNOS renders it less active. Several studies demonstrated that the 
actions of CaM are thought to be facilitated in cells by the recruitment of Hsp90 to eNOS 
and from the dissociation of eNOS from Cav-1 (Brouet et al., 2001). Our analysis showed 
that the incubation with UII induced phosphorylation of eNOS in HCC. This effect was 
inhibited by pre-tratment with wortmannin,  Akt inhibitor, but not with geldanamicin, 
Hsp90 inhibitor. In addition, in vitro functional studies on HCC strips proved that UII 
induced relaxation was inhibited by pre-tretment with either wortmannin and 
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geldanamicin. Thus, based on these data, we propose that UII, by an increase of 
intracellular calcium, cause an activation of eNOS via Akt and Hsp90, following in NO 
release.  
In conclusion  U-II can be added to the other vasoactive factors (noradrenaline, 
endothelins, angiotensins, NO, VIP, and related peptides, prostanoids, H2S) in the 
physiology of erectile function. 
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CHAPTER 4 
 
Platelet cGMP: 
 a new biological marker  
of PDE5 inhibitors efficacy
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4.1 Erectile dysfunction: diagnosis and therapy 
Erectile dysfunction, as mentioned before, is the consistent or recurrent inability of a 
man to attain and/or maintain a penile erection sufficient for sexual activity (2nd 
International Consultation on Sexual Dysfunction-Paris, June 28th–July 1st, 2003). Male 
ED represents a worldwide and multi-cultural condition with prevalence rates between 19 
and 74% in the age groups 40 - 80 years (Koskimaki et al., 2000; Chew et al. 2000; 
Johannes et al., 2000). It is well documented the negative impact of ED on the quality of 
life (Willke et al., 1998; Wagner et al., 1996). Through history, impotence has influenced 
the society in two major ways. First, there has often been an immense associated sense of 
humiliation; second it has a major impact on determining the validity of marriage in low. 
These aspects have a negative impact on the quality of life, particularly on sexual 
relationships with the partner and in relations with relatives and friends (National Institute 
of Health Consensus Development Panel on Impotence. 1993). Thus, the importance of a 
well-timed diagnosis is crucial event. Actually ED is evaluated by medical questionnaire 
scores. In 1997 Rosen and co-workers developed the International Index of Erectile 
Function (IIEF), a new method to diagnose erectile dysfunction. In this method were 
identified five factors or response domains: (1) erectile function (IIEF-EF); (2) orgasmic 
function (IIEF-OF); (3) sexual desire (IIEF-SD); (4) intercourse satisfaction (IIEF-IS); (5) 
overall satisfaction (IIEF-OS) (Rosen et al., 1997). In particular, IIEF-EF, a 15-item 
questionnaire, has been developed and validated as a brief and reliable self-administered 
scale for assessing erectile function (Figure 34). 
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Figure 34: The International Index of Erectile Function (IIEF) Questionnaire. 
International Index of Erectile Function (IIEF): 
1. Over the past 4 weeks, how often were you able to get an erection during sexual activity? 
2. Over the past 4 weeks, when you had erections with sexual stimulation, how often were your erections hard enough for 
penetration? 
3. Over the past 4 weeks, when you attempted sexual intercourse, how often were you able to penetrate (enter) your partner? 
4. Over the past 4 weeks, during sexual intercourse, how often were you able to maintain your erection after you had 
penetrated (entered) 
your partner? 
5. Over the past 4 weeks, during sexual intercourse, how difficult was it to maintain your erection to completion of 
intercourse? 
6. Over the past 4 weeks, how many times have you attempted sexual intercourse? 
7. Over the past 4 weeks, when you attempted sexual intercourse how often was it satisfactory for you? 
8. Over the past 4 weeks, how much have you enjoyed sexual intercourse? 
9. Over the past 4 weeks, when you had sexual stimulation or intercourse how often did you ejaculate? 
10. Over the past 4 weeks, when you had sexual stimulation or intercourse how often did you have the feeling of orgasm or 
climax (with 
or without ejaculation)? 
11. Over the past 4 weeks, how often have you felt sexual desire? 
12. Over the past 4 weeks, how would you rate your level of sexual desire? 
13. Over the past 4 weeks, how satisfied have you been with your overall sex life? 
14. Over the past 4 weeks, how satisfied have you been with your sexual relationship with your partner? 
15. Over the past 4 weeks, how do you rate your confidence that you can get and keep an erection? 
IIEF score system: 
Questions 1,2,3,4,7,9: 
0= No sexual activity; 1= Almost never or never; 2= A few times (much less than half the time); 3= Sometimes (about half 
the time); 
4= Most times (much more than half the time); 5= Almost always or always. 
Question 5: 
0=Did not attempt intercourse; 1= Not difficult; 2=Slightly difficult; 3= Difficult; 4= Very difficult; 5= Extremely difficult 
Question 6: 
0=No attempts; 1= One to two attempts, 2= Three to four attempts; 3= Five to six attempts; 4= Seven to ten attempts; 
5= Eleven or more attempts 
Question 8: 
0=No intercourse; 1=Not enjoyable; 2= Not very enjoyable; 3= Fairly enjoyable; 4= Highly enjoyable; 5= Very highly 
enjoyable 
Question 11: 
1= Almost never or never; 2= A few times; 3= Sometimes; 4= Most times; 5= almost always or always 
Question 12,15: 
1= Very dissatisfied; 2= Moderately dissatisfied; 3= About equally satisfied and dissatisfied; 4= Moderately 
satisfied; 5= Very satisfied 
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This instrument is psychometrically sound and clinical setting. In addition, IIEF-EF is 
available in 10 languages for use in multinational clinical trials, and it demonstrate 
adequate sensitivity and specificity for detecting treatment-related changes in erectile 
function in patient with ED (Rosen et al., 1997).  
 The reliability as well as consistency of  IIEF was originally tested on a large number 
of patients taking sildenafil. However, about 2.5 years after the launch of sildenafil, 
clinical practice surveys demonstrated that 38–51% of patients discontinued sildenafil 
therapy for lack of efficacy (Souverein et al., 2002). Following the launch on the market of 
vardenafil and tadalafil, patients who were non-responders to sildenafil were scheduled 
successfully for treatment with another PDE5 inhibitor, although they all share the same 
mechanism of action (Stroberg et al., 2003; Rubio-Aurioles et al., 2006).   
PDE5 inhibitors, in fact, decrease the degradation of cGMP. The central role of cGMP 
signalling in erectogenic response of penile tissue to sexual stimuli is now well established 
(Burnett. 2006). In particular, NO activates guanylyl cyclase causing an increase in cGMP, 
which activates cGMP-dependent protein kinase (PKG), resulting in smooth muscle 
relaxation, dilation of  the sinusoids, increase in blood flow and enhancing erection 
(Hofmann, 2005; Lincoln et al., 2001; Sausbier et al,. 2000). PDE5 break down cGMP to 
the inactive 5’-GMP (Gopal et al., 2001).The mentioned PDE5 inhibitors, known as 
competitive inhibitors, have high affinity for the PDE5 catalytic site thereby blocking 
cGMP access to the site and fostering cGMP accumulation (Blount et al., 2004; Ballard et 
al., 1998; Turko et al., 1999).  
Several clinical studies showed that IIEF can provide information mainly on sexual 
functioning but is not helpful in clarifying differences among the inhibitors used in clinical 
studies (Stroberg et al., 2003; Rubio-Aurioles et al., 2006). Indeed, it mainly measures 
sexual functioning (Rosen et al., 1997), is sensitive to placebo, and does not permit 
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addressing the potential difference in mechanism among drugs. However, various clinical 
trials are developed to a careful evaluation of ED. The most used tests, with IIEF, are 
Sexual Encounter Profile (SEP) and Rigiscan. SEP is a diary consisting of yes/no-type 
questions that enables both the patient and his partner to evaluate sexual encounters 
(Figure 35).  
  
 
 
 
Figure 35: The Sexual Encounter Profile (SEP) diary. 
 
 
It has been indicated a high degree of correlation between erection and intercourse 
satisfaction rating between SEP and IIEF measure in patients with mild to moderate 
degrees of ED (Rosen et al., “The sexual encounter profile (SEP): validation of a simple 
event log for sexual function assessment”. Unpublished). The Rigiscan, instead, represents 
an objective method to evaluate penile tumescence and rigidity.  Since each of these 
measure has certain in advantages and limitation, these three tests are frequently used all 
together to have an accurate evaluation of both ED and treatment efficacy.   
Patient Sexual Encounter Profile (SEP) 
Date of Sexual Encounter ______/______/____ (day / month / year) 
Time of Sexual Encounter______ 
1. Were you able to achieve at least some erection (some enlargement of the penis)? 
If yes, place 1 in the box and CONTINUE. If no, place 0 in the box and STOP. 
2. Were you able to insert your penis into your partner’s vagina? 
If yes, place 1 in the box. If no, place 0 in the box. 
3. Did your erection last long enough for you to have successful intercourse? 
If yes, place 1 in the box. If no, place 0 in the box. 
4. Were you satisfied with the hardness of your erection? 
If yes, place 1 in the box. If no, place 0 in the box. 
5. Were you satisfied overall with this sexual experience? 
If yes, place 1 in the box. If no, place 0 in the box. 
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Another important issue, is that patients often report facilitated erections also when 
plasma concentrations of PDE5 inhibitors drop well below the therapeutic level (Moncada 
et al., 2004; Young et al., 2005; Shabsigh et al., 2006) 
The drugs differ substantially in the rate of clearance from plasma: t½ of plasma 
clearance is 4 hours for sildefail or vardenafil compared to 18 hours for tadalafil. However 
studies indicate that men still have facilitated erections 12 hours after sildenafil or 
vardenafil dosing, likewise 36 hours after tadalafil dosing (Moncada et al., 2004; 
Valiquette et al., 2005).  
Many hypothesis are reported in literature but no one mechanism has been 
demonstrated to explain the prolonged effect of PDE5 inhibitors (Francis et al., 2008).  
PDE5, purified in 1980 by Francis and colleagues from rat lungs (Francis and Corbin 
1988), a cGMP-specific enzyme that hydrolyzes cGMP, is one of the targets for the action 
of NO.  The tissue distribution of PDE5 generally coincides with that of PKG, probably 
because both enzymes are the principal intracellular receptors of cGMP. Moreover, PKG is 
an excellent in vitro catalyst for the phosphorylation of PDE5 (Thomas et al., 1990). PDE5 
has a typical cytosolic localization with high levels in smooth muscle, platelets, kidney and 
in some zones of the central nervous system (Francis and Corbin 1999; Kotera et al.,  
2000; van Staveren et al., 2004; Dolci et al., 2006). 
On these basis we have evaluated if platelet cGMP could  represent an objective 
measure of PDE5-inhibitor efficacy and duration.   
In our studies we have evaluated cGMP level in a population of 46 men with ED and 
we have correlated the values obtained with the clinical variables (IIEF, SEP and 
Rigiscan). 46 ED patients were enrolled and randomly divided into two groups, one treated 
with vardenafil and one with placebo. Clinical analysis and evaluation of platelet cGMP 
were performed before and after 6 weeks of treatment.  
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4.2  Materials and methods 
 
4.2.1 Washed human platelet preparation 
Fresh blood (20 ml) from human donors anticoagulated with citrate (final concentration 
3.8 %, w/v) was centrifuged at 800 rpm for 10 min to obtain the so-called platelet-rich 
plasma (PRP) as a supernatant. A 1/10 volume of ACD solution (85 mM Na3-citrate, 111 
mM d-glucose, 71 mM citric acid, pH 4.4) was added to 9/10 volume of PRP. After 
centrifugation (2000 rpm for 12 min) the cell pellet was resuspended in Ca2+/Mg2+-free 
HEPES–Tyrode buffer (134 mM NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.36 mM 
NaH2PO4, 5 mM HEPES, 5 mM glucose, 0.5% (w/v) bovine serum albumin, pH 7.4) and 
the cell number was determined and adjusted to final concentration required (Dunkern et 
al., 2005). 
 
4.2.2 Preliminary studies 
Preliminary studies were performed on washed platelets harvested from healthy 
volunteers. A preliminary time course study was performed incubating different numbers 
of washed platelets (3x 104 to 5x105/µl) for 5, 15, or 30 min with either sodium 
nitroprusside (10, 100, 1000 µM) or diethylamine NONOate (DEA-NONOate, 1, 10, 100 
µM) to select the experimental condition for the concentration of platelets, the stimulus 
and the time of incubation. From these data, the experimental condition were: (1) platelet 
concentration 5x105 µl, (2) incubation time 30 min, and (3) DEA-NONOate as stimulus. 
Indeed, DEA-NONOate gave more reproducible and reliable results because it 
spontaneously dissociates in a pH-dependent, first-order process with a half-life of 2 min at 
37°C, pH 7.4, to liberate 1.5 mol of NO per mole of parent compound (Keefer et al., 
1996). cGMP content was measured by using a cGMP enzyme immunoassay kit. 
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4.2.3 Platelet assay standardization in healthy volunteers 
In a preliminary study, a group of six normal voluntary subjects (24–30 yr of age) were 
enrolled to assess the feasibility of the assay. Volunteers gave a blood sample (20 ml)  
before and 1 h after taking vardenafil (20 mg) (eg, under the peak of the area under the 
curve [AUC]). Platelets were used to select a suitable NO donor and the optimal incubation 
time for the ex vivo platelet assay. 
 
4.2.4 Evaluation of vasodilator-stimulated phosphoprotein (VASP) in human platelets 
We have investigated on the mechanism of the prolonged effect of PDE5 inhibitors. 
Francis et al hypothized that the prolonged effect of PDE5 inhibitors could be caused by 
their permanence in the cell. From this hypothesis, since cGMP signalling cascades relaxes 
smooth muscle and inhibit platelet activation, it was speculated that VASP mediates these 
effects by modulating actin filament dynamics and integrin activation. The 
phosphorylation of VASP at serine 239 is cGMP-dependent protein kinase (PKG). 
Therefore, VASP phosphorylation level are considered to reflect levels of cGMP in 
platelets (Aszodi et al., 1999; Hauser et al., 1999). On these basis we have evaluated the 
phosphorylation of VASP in human platelets after 6 weeks of  treatment with either 
placebo or vardenafil. 
 
4.2.5 Western blot analysis 
Human platelets, resuspended in Ca2+/Mg2+-free HEPES–Tyrode buffer (134 mM 
NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.36 mM NaH2PO4, 5 mM HEPES, 5 mM glucose, 
0.5% (w/v) bovine serum albumin, pH 7.4) and adjusted to 5 × 105 platelets/µl, were 
homogenized in modified RIPA buffer (Tris-HCl 50 mM, pH 7.4, Triton 1%, sodium 
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deoxycholate 0.25%, NaCl 150 mM, ethylenediaminetetraacetic acid 1 mM, 
phenylmethylsulphonyl fluoride 1 mM, aprotinin 10 mg/mL, leupeptin 20 mM, NaF 1 mM, 
sodium orthovanadate 1 mM) by liquid nitrogen. Protein concentrations of cell lysates 
were estimated by the Bio-Rad protein assay using BSA as standard. Equal amounts of 
protein (30 µg) of the cell lysates were dissolved in Laemmli’s sample buffer, boiled for 5 
min, and subjected to SDS-polyacrylamide gel electrophoresis (8% polyacrylamide). 
Western blotting was performed by transferring proteins from gel to a sheet of 
polyvinylidene fluoride membrane at 250 mA for 60 min at room temperature. The filters 
were then blocked with phosphate-buffered saline (PBS) containing 5% non-fat dry milk 
(PM) and NaF (50mM) for 45 min at room temperature and incubated with mouse 
monoclonal antibody to VASP (phosphorylated) (pSer239) (16C2) (1:3000) in 1x PBS, 5% 
non-fat dried milk and 0.1% Tween 20 (PMT) overnight at 4°C. Than the membranes were 
extensively washed by in PBS containing 0.1% v/v Tween 20, before incubation for 2 
hours with horseradish peroxidase-conjugate anti mouse secondary antibody (1:5,000). 
Membranes were then washed and developed using enhanced chemiluminescence 
substrate. The same membranes were incubated overnight at 4°C with mouse monoclonal  
anti VASP antibody (IE273) (1:4000). Filters were exposed to ECL after 2 hours of 
incubation with horseradish peroxidise-conjugate antimouse antibody (1:5000). To 
ascertain that blots were loaded with equal amounts of protein lysates, they were also 
incubated in the presence of the mouse β-actin antibody. The protein bands were 
densitometrically analysed with a model GS-800 imaging densitometer. 
 
4.2.6 Study design and population 
Patients were selected following an interview at the time of their visit. All patients gave 
written informed consent before random assignment to one of the two study arms. The 
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protocol was approved by the ethical committee of Federico II University of Napoli. Table 
3 lists the patient inclusion and exclusion criteria. 
 
 
 
 
 
 
Table 3: Inclusion and exclusion criteria 
 
 
 
 
 
 
 
 
To perform the study, 46 PDE5-I–naive patients with ED were enrolled and were 
scheduled either on placebo (n = 23) or on vardenafil, 5mg (n = 23) at bedtime for 6 wk 
daily (Montorsi et al., 2008; De Young et al.,2008; Carson et al., 2004). Study protocol 
assumed a run-in period of 1–6 wk during which patients were enrolled, and, if eligible, the 
IIEF-EF and SEP questionnaires were administered. Thereafter a provocative real-time 
VSS-Rigiscan section was performed. All patients donated 20 ml of venous blood for 
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platelet cGMP and VASP determination. The clinical evaluations as well as the sample 
blood were repeated after 6wk of treatment in both study arms within 12 h from the last 
drug dose. Table 4 lists the baseline characteristics of the patients who participated in the 
study. The patient groups were balanced, and the baseline IIEF-EF values were not 
different among the groups considered. All 46 of the patients enrolled completed the study. 
The sample size was computed considering an a error equal to 0.05, a β-error equal to 0.20 
(power equal to 80%), and an increase from 13 to 18 points of the IIEF with a standard 
deviation of 6. The 5-point increase of the effect size was selected because it is generally 
considered the minimum clinically significant response to the drug. 
 
 
 
 
 
Table 4: Characteristics of patients at baseline  
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4. 2.7 Real-time visual sexual stimulation-Rigiscan 
The provocative real-time Rigiscan-coupled VSS was used (Mizuno et al., 2004). 
Patients were asked to watch an erotic movie during the Rigiscan recording (30 min). 
 
4.2.8 Ethical permission 
The protocol will be submitted to the Ethics Committee of the Medical School of the 
University of Naples. Healthy volunteers and ED asked to sign an informed consent. 
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4.3 Resultes 
 
4.3.1 Healthy volunteers 
Platelet cGMP levels were evaluated in 6 healthy volunteers before and 1 hour after 
treatment with vardenafil, 20 mg. The results, reported in Figure 36,  showed a dose-
dependent Challenged with diethylamine (DEA)-NONOate (1, 10, and 100 mM) in both, 
before and after treatment. In addition 1 hour after treatment with vardenafil 20 mg there 
was a significantly increase in cGMP than values observed at baseline. 
 
 
 
 
 
  
 
 
 
Figure 36: Effect of vardenafil on platelet  cGMP in healthy volunteers. 
Platelet harvested from healthy volunteers prior to or 1 h following the administration of vardenafil, 20 mg, 
were challenged with diethylamine (DEA)-NONOate (1, 10, and 100 mM). Platelet cGMP significantly 
increased in the vardenafil group (n = 6; p = 0.003). 
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4.3.2 Effect of Vardenafil on platelet cGMP in patients with ED 
Platelet cGMP levels were evaluated following in vitro stimulation with diethylamine 
(DEA)-NONOate (1, 10, and 100 mM) prior to and after 6 wk following the treatment with 
either placebo or vardenafil. Data reported in figure 37 showed that in placebo group 
(Figure 37 a) there was not challenge in cGMP level at all doses of DEA-NONOate. On 
the contrary, after 6 weeks of vardenafil treatment (Figure 37 b) there was an increase of 
cGMP level at all doses of DEA-NONOate. To better analyzed GMP release, the AUC 
variation from baseline, in each dose-response curve, was used for both placebo and 
vardenafil. The treatment produced a significant increase in cGMP (p<0.05; Fig. 37 c). 
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Figure 37: Effect of vardenafil, 5 mg, versus placebo. 
The production of cyclic guanosine monophosphate (cGMP) following stimulation in vitro with diethylamine 
(DEA)-NONOate (1, 10, and 100 mM) was evaluated prior to or after 6 wk following the treatment with 
either (a) placebo or (b) vardenafil. (c) The same data were analyzed as area under the curve (AUC) and 
expressed as changes in AUC. The analysis demonstrates a significant increase ( p < 0.05) in platelet cGMP 
in the vardenafil group versus placebo. 
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4.3.3 Effect of vardenafil in clinical parameters 
 
The IIEF-EF (Figure 38 a), the SEP (Figure 38 b) and  the VSS-Rigiscan (Figure 39) 
score were analyzed by comparing within each group, the response prior to and after the 
treatment. Analyzing absolute data of IIEF-EF and SEP prior and after treatment (Figures 
38 a and b), was observed a significant challenge in both group, placebo and vardenafil. 
However, when the δ increase in both IIEF-EF (Figure 38 c) and SEP (Figure 38 d) were 
compared, they did not reach statistical significance between placebo and vardenafil group. 
In contrast the VSS-Rigiscan score clearly showed a significant amelioration in the 
vardenafil but not in placebo group as absolute data (Figure 39a; p < 0.05). When data 
were evaluated as δ increases, calculated as the difference between the effect prior to and 
after the treatment, it has been showed a significant difference between placebo and 
vardenafil group. 
 Thus it seems that although IIEF-EF and SEP are sensitive to the placebo effect, 
platelet cGMP and VSS-Rigiscan are not. 
To summarize the clinical response to treatment (placebo or drug), a factorial analysis 
was performed on IIEF-EF, SEP, and VSS-Rigiscan. This analysis was necessary to 
compare parametric with nonparametric data. The first component was strictly correlated 
with both the IIEF-EF and SEP scores; the second accounted for the VSS-Rigiscan 
measurement. The multiple linear regressions between these two components and the AUC 
variation were used to assess the degree of association between the clinical and the cGMP 
response. IIEF-EF and SEP did not significantly correlate with cGMP as opposed to the 
Rigiscan measure that reached statistical significance ( p = 0.037). 
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Figure 38: International Index of Erectile Function (IEF), sexual encounter profile (SEP). 
(a) IIEF and (b) SEP were significantly increased after 6 wk of treatment with either placebo or vardenafil, 
5mg. However, the d increase, calculated as the difference between the effect prior to and after the treatment, 
in (c) IIEF and (d) SEP were not significantly different between placebo and vardenafil. 
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Figure 39:visual sexual stimulation (VSS)-Rigiscan. 
VSS-Rigiscan data were calculated as the maximum rigidity achieved and expressed as a percentage. (a) 
Placebo did not cause any significant increase in VSSRigiscan response after 6 wk of treatment. Conversely, 
(a) vardenafil treatment caused a significant increase in the response. (b) The δ increase in VSS-Rigiscan 
response, calculated as the difference between the effect prior to and after the treatment, was significantly 
different between the placebo and the vardenafil group. 
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4.3.4 Protein kinase G activation 
 
Determination of p-VASP/VASP protein expression was assumed as a measure of the 
persistent activation of the protein kinase G (PKG) (Oelze M. Circ Res 2000;87:999–
1005), and as such, a marker of the cGMP platelet accumulation beyond the half-life of 
vardenafil. Western blot analysis was performed on washed human platelets from either 
healthy volunteers prior and after treatment and from placebo and vardenafil group after 6 
weeks of treatment (Figure 40 a).     
The densitometric analysis, expressed as p-VASP/VASP ratio, showed that there was a 
significantly ( p < 0.05) increase in patients taking vardenafil compared with the placebo 
group (Figure 40 b). 
 
 
 
 
 
 
 
 
Figure 40: Vasodilator-stimulated phosphoprotein (VASP) and phosphorylated (p)-VASP evaluation 
in platelets. (a) A representative western blot for VASP and p-VASP. (b) Densitometric analysis shows a 
significant ( p < 0.01) change in the p-VASP/VASP ratio following the 6 wk of treatment with vardenafil 
versus placebo as opposed to the acute treatment in healthy volunteers. NS = not significant. 
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4.4 Discussion 
PDE5 inhibitors are the mainstay in the treatment of ED, pathological condition 
characterized by the inability to achieve or maintain an erection sufficient for satisfactory 
sexual performance. Sildenafil (Viagra©) was the first drug to be marked for oral treatment 
of ED. By inhibiting PDE5, sildenafil increases the intracellular concentration of cGMP, 
causing amplification of the endogenous NO-cGMP pathway (Gopal et al., 2001). In the 
clinical studies on PDE5 inhibitors the primary effect measure is the IIEF, a validated 
questionnaire that measures the degree of ED and its improvement following therapeutic 
treatment (Rosen et al., 1997). In addition, also Sexual Encounter Profile (SEP), another 
widely questionnaire was diffused to detect treatment related changes in patient with ED 
(Rosen et al., “The sexual encounter profile (SEP): validation of a simple event log for 
sexual function assessment”. Unpublished). While from one side the introduction of these 
simple and widely accepted questionnaires has given the possibility to quantify the degree 
of ED, the introduction in the market of tadalafil (Cialis©) and vardenafil (Levitra©) has 
revealed some weak point and raised data interpretation problems. The major problems of 
these tests are represented by their non objective measure of evaluation  To have an 
accurate evaluation of both ED and treatment efficacy also Rigiscan is used in association 
with questionnaire tests. However in a several studies IIEF does not well correlate with 
rigiscan test (Yang et al., 2006;  Melman et al., 2006).  
The main goal of this study was to define if platelet cGMP could be used as a reliable 
marker of PDE5 activity. In preliminary study performed on healthy volunteers we have 
demonstrated that, following an acute administration of vardenafil (20 mg), platelets 
harvested under the AUC pharmacokinetic peak (Klotz et al,. 2001; Gupta 2005)  showed a 
twofold increase in cGMP, respect basal condition, ensuring a high sensitivity to the assay. 
To achieve a prolonged stimulation of the cGMP/PKG pathway (Giuliano 2009), patients 
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took 5 mg vardenafil each day for 6 weeks at bedtime versus placebo. The bedtime 
positioning of the therapy was selected to achieve the best possible patient compliance. In 
addition all patients completed the IIEF-EF and SEP questionnaires and performed the 
provocative rigiscan.  
Our data, obtained by platelet cGMP evaluation, highlighted a statistical significance 
increase of cGMP levels in patients treated with chronic administration of a low dose of 
vardenafil versus placebo group. These results didn’t fit with IIEF-EF and SEP scores. In 
fact, even though the questionnaire tests showed a significantly amelioration in both the 
placebo and the vardenafil group after 6 wk of treatment, the increase in both IIEF-EF and 
SEP were not significantly different between placebo and vardenafil. The discrepancies 
showed between cGMP evaluation and both IIEF-EF and SEP implies that the placebo 
effect influenced the questionnaires. Conversely, the rigiscan data analysis demonstrated 
that there was a significant amelioration in the patients treated with vardenafil versus 
placebo group. The evaluation of a relation with the variables, by using a factorial analysis, 
showed that platelet cGMP displayed a weak association with IIEF-EF and SEP, whereas a 
significant correlation was found with rigiscan. Since platelet cGMP data fit with a clinical 
objective measurement (eg, VSS-Rigiscan but not with either IIEF-EF or SEP), we can 
define platelet cGMP as a possible biomarker of PDE5 inhibitor efficacy in the treatment 
of ED. 
Plasma levels of vardenafil could not explain the significant effect observed because 
the platelet cGMP measurement and VSS-rigiscan were performed 12 h after dosing. In 
fact several studies reported that t½ of plasma clearance is 4 hours for vardenafil. Thus our 
results compared to plasma levels of vardenafil, could not explain the significant effect 
observed because the platelet cGMP measurement and VSS-rigiscan were performed 12 h 
after dosing. However, our data fit well with clinical studies reporting that men still have 
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facilitated erections when the levels of PDE5-I are well below that is considered the 
therapeutic plasmatic concentration (Moncada et al., 2004; Young et al., 2005; Shabsigh, 
et al,. 2006). On these basis, another crucial point of this study is the evaluation of the 
mechanism of the prolonged effect of PDE5 inhibitors. Many hypothesis are reported in 
literature but no one mechanism has been demonstrated. Francis et al. sustained that the 
prolonged effect of PDE5 inhibitors could be explained by a prolonged exposure of PDE5 
to inhibitors (Francis et al., 2008 ). On this hypothesis, if drug is not cleared in parallel 
with clearance from plasma, PDE5 activity would continue to be blocked and high level of 
cGMP resulting from earlier sexual stimulation would be preserved since PDE5 is the main 
cGMP-hydrolyzing PDE in cells. Continued activation of PKG would sustain 
phpsphorylation events mediated by this enzyme including phosphorylation of PDE5 and 
PKG autophosphorylation (Figure 41). Evaluation of PKG phosphorylation in platelets is 
normally carried out by evaluating as surrogate marker a vasodilator-stimulated 
phosphoprotein (VASP) that is the major substrate for cGMP-dependent PKG in human 
platelets (Oelze et al., 2000). Our western blot analysis, performed on VASP activation, 
clearly show that the prolonged therapy with vardenafil but not placebo leads to a 
significant change in the p-VASP/VASP ratio and thus of PKG phosphorylation. 
Interestingly, the p-VASP/VASP ratio change in healthy volunteers following an acute 
administration of vardenafil was not significant.  
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Figure 41: Potential process that could contribute to persistence of the effect of activation of the 
cGMP signalling pathway in vascular smooth muscle cells in presence of PDE5 inhibitors (Francis et 
al. 1997).  
 
On the basis of the hypothesis reported by Francis et al., our data strongly suggest that 
most likely a prolonged exposure to vardenafil coupled with a sexual stimulus is necessary 
to trigger the cascade of events just described. In addition, it is feasible to assume that what 
we have seen in platelets reflects what is happening in competent cells in the human penile 
tissue (eg, endothelial and smooth muscle cells).  
In conclusion platelet cGMP level  could represent a relative simple assay to provide 
information on the activity and duration of PDE5 inhibition within and over plasma levels. 
Since its correlation with a clinical objective measure, it could be helpful in interpreting 
and/or correcting the data obtained by IIEF-EF and SEP. This characteristic makes the 
platelet cGMP assay a useful tool to be used in future ED clinical studies, for example on 
patients who are nonresponders to a PDE5-I scheduled as an alternative or in comorbidity 
conditions (diabetes, lower urinary tract symptoms, etc). 
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Conclusions 
Erectile dysfunction can be due to a number of different pathophysiological events. On 
these basis ED may be classified as psychogenic, organic (neurogenic, hormonal, 
vasculogenic and drug-induced), and mixed. Vasculogenic (arterial and cavernosal) ED is 
characterized by impaired veno-occlusive mechanism and inadequate arterial inflow. 
Peyronie’s disease could represent one of this pathological process. In fact Peyronie’s 
disease (PD) is a connective tissue disorder involving the growth of fibrous plaques of 
tunica albuginea of the penis with curvature and distortion, usually during erection, penile 
pain and erectile dysfunction (Gelbard et al., 1990). However, PD is a poorly understood 
disorder on molecular and physiopathological basis also due to the lack of appropriate 
animal model. We have given a contribute in the understanding of this pathology by  
discovery a new animal model of Peyronie Disease naturally occurring: Thight skin (Tsk) 
mouse. In fact Tsk mouse replicates conditions that are similar enough to human disease. In 
particular, (i) Tsk mice spontaneously develop the disease with age, (ii) several mediators 
that have been implicated as the major players in the human disease are involved and (iii) 
this animal model shares many morphological, histological and biochemical features with 
the human disease. For all these characteristics Tsk mouse represents the first example of 
naturally occurring model of PD in laboratory animals. 
Since PD represents a particular case of organic ED which is generally caused by the 
breaking of the balance vasorelaxant and vasoconstrictor factors, in the second part of 
these studies we have looked for a pathway involved in this balance. Our attention has 
been focused on urotensin II (UII), an endogenous, vasoactive peptide and its receptor 
(GPR14 or UT receptor). At first we have showed that GPR14 is expressed in the rat 
corpus cavernosum and in anesthetized rats, intracavernous administration of UII causes an 
increase in ICP. Also HCC possesses U-II receptor that is located predominantly on the 
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endothelium. The receptor is functional and mediates an endothelium-dependent relaxation 
that involves the L-arginine/NO pathway. In particular, UII  activates eNOS via Akt and 
via Hsp90, following in NO release and thus relaxation. These observations may help to 
unravel the complex mechanisms underlying the pathophysiology of human penile erection 
and may lead to the development of novel therapeutic approaches in the treatment of ED 
and sexual arousal disorders. 
Since the difficulty in ED diagnosis and evaluation of ED treatment efficacy, in the last 
part of these studies we have looked for a new, objective, non invasive and reliable 
methods. In our clinical study it has been showed that platelet cGMP could represent a 
valuable marker for PDE5 activity on ED. Indeed this measure is probably less sensitive to 
the placebo effect. Thus it represents an important objective measure that helps to 
interpreter and/or correct the data obtained by IIEF and SEP. In addition, by measuring 
cGMP it could be possible to better define those patients that are non-responders. Finally 
we show evidence for a possible biochemical mechanism of action that can justify the 
prolonged activity of PDE5 inhibitors beyond their half life.  
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